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ABSTRACT 
 
There is a continuing need to improve anti-tubercular drugs due to the development of 
resistance towards existing drugs. In some cases, metal complexes are known to improve the 
bioavailability of drugs. Hence the present study looks at the use of metal complexes of anti-
tubercular drugs to improve the permeability and bioavailability of the drugs. The anti-
tubercular drugs isoniazid (ISO), ethambutol (EMB), para-aminosalicylic acid (PAS), 
rifampicin (RFN) and pyrazinecarboxamide (PZA) were used in this study. 
Since the solubility and hence permeability and bioavailability of the drugs depend on their 
solution speciation, the equilibrium constants for the reaction of H+, Cu(II), Ni(II) and Zn(II) 
with the ligands were measured, in aqueous solution, at 25  0.01C and an ionic strength of 
0.15 M (NaCl) using glass electrode potentiometry.  
The structures of the complexes with EMB, ISO and PAS were investigated using ultraviolet-
visible spectroscopy. The visible spectra obtained for the different species of EMB in solution 
were typical of Cu(II) and Ni(II) complexes. The spectra found for the various species of ISO 
and PAS in solution were also characteristic of their Cu(II) complexes. The results from the 
visible spectra support the structures postulated from the potentiometric data. 
This study also considered membrane permeability and absorption using a Franz cell and 
octanol/water partition coefficients. Partition coefficient studies showed that ISO and PZA and 
their complexes are hydrophilic while RFN and PAS and their complexes are lipophilic. The 
incorporation of a metal-ion improves the lipophilicity/hydrophilicity properties of the ligand. 
The presence of metal greatly enhanced the permeation of ISO through an artificial membrane 
in the order Cu(II) > Zn(II) > Ni(II) > ISO. A significant improvement was also found when 
Cu(II) was incorporated into the RFN system with an enhancement factor of 20. Zn(II) was 
vii 
 
able to improve the permeation of PAS with an enhancement ratio of 2. The incorporation of 
Cu(II), Ni(II) and Zn(II) does not affect the flux and permeability coefficient of PZA. 
Since the drugs are administered in tablet form, attempts were made to synthesise the metal 
complexes of the drugs in solid form.  X-ray crystallography could then be used to confirm the 
solution structures.  Co-precipitation, refluxing and mechanochemical methods (neat and 
liquid-assisted co-grinding) were employed to synthesise Cu(II), Ni(II) and Zn(II) complexes 
of the series of anti-tubercular drugs. However, despite exhaustive efforts, all experiments 
resulted in the formation of only physical mixtures of the reactants, as revealed by 
chromatographic and X-ray diffraction methods. This impelled the use of the solvothermal 
method as an alternative technique. ISO and PZA metal complexes were synthesised via this 
method. Unexpected products were obtained, as indicated unambiguously by single crystal X-
ray diffraction, and a probable mechanism for their formation was postulated.  
The incorporation of metals into anti-tubercular drugs has a significant influence in improving 
the permeability of the parent drug. It was found that the presence of Cu(II), Ni(II) and Zn(II) 
improved the permeability coefficient of ISO, while Cu(II) improved RFN and Zn (II) 
enhanced that of PAS.  
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1.1 Introduction 
Tuberculosis (TB) is a global health problem that results in several million deaths annually 
worldwide.1 It is the leading cause of death by a single treatable infectious disease killing 
approximately 5000 people per day throughout the world as the World Health Organisation 
(WHO) reported 1.8 million deaths due to TB in 2008.  The burden of TB is particularly high 
in Africa where the case rate was reported to be 281 per 100 000 people.2  
The TB problem is inequitably distributed among men and women. Of the predicted 8.7 million 
TB cases and 1.4 million deaths caused by TB globally in 2011, about one-third occurred 
among women (2.9 million TB cases and 0.5 million deaths).1 The scientific community has 
recognised that gender-related differences in health may be higher than is acknowledged and 
thus necessitate the need for routine gender-correlated study.3-5 
The WHO has proposed a framework and priorities for research on sex and TB to address the 
knowledge gap.6   The WHO has also reinforced approaches of analysing the role of gender in 
health, and to evaluate and address, harmonising gender-related health disparities.7 
Currently, the question of whether the gaps are due to sex-related difference, social, cultural 
practices and different social role of men and women or both have been studied.8,9   Numerous 
reviews have studied gender-linked barrier and delay in seeking TB care.10-13 According to 
studies, some of the contributing reasons that make women experience more obstacles and a 
longer delay than men include individual financial level, stigma and lower health literacy in 
south-east Asia.  
Over 500 000 children were identified with TB in 2012, and 74 000 died.14 Diagnosing TB is 
highly challenging in children because of the production of the insufficient sputum sample. 
Less than 15% of the TB in children are acid-fast smear-positive. 30-40% of the cases are 
cultured confirmed.15 The risk of TB is high among the population living in poverty, low 
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socioeconomic groups, low-income, immune suppressed and extreme age (elderly and 
children) groups, migrants and people exposed to animals. Much of this morbidity and 
mortality of TB occurs in children, contributing to the number of TB cases in the future. 
In developing countries, TB is a leading cause of death.16 An important associated problem is 
the alarming increase of drug resistant microbial strains (MDR-TB) that makes difficult the 
effective control of the disease. To further complicate the matter, drug-drug interactions 
between TB medicines and anti-HIV treatments or other chronic illness medications such as 
those used in people with diabetes should also be considered.17-21   This has escalated the 
treatment of TB in the past decades. Due to this critical situation, innovation in TB drug 
discovery and evolving strategies to bring a new agent with the best performance is a current 
health priority.22 Areas in which TB is prevalent are shown in Figure 1.1. 
 
 
Figure 1.1 Map indicating TB-affected areas.1 
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1.2       Pathogenesis 
TB is an ancient disease; the causative agent is Mycobacterium tuberculosis. It predominantly 
affects the lungs, but it can also affect organs in the central nervous system, lymphatic system, 
and circulatory system among others.23 TB is transmitted mostly through airborne spread via 
the respiratory route when a patient coughs or sneezes. One strain of TB, Mycobacterium Bovis, 
can be caused by drinking un-boiled milk.24 TB is categorised as being either latent or active. 
In latent TB, the bacteria are inactive but present in the body. The patient has no symptoms and 
is not contagious. In active TB, the bacteria make the patient ill and are infectious. About 10% 
of people with latent TB develop active TB years after the initial infection. This active TB 
occurs when the immune system is weakened, for example by chemotherapy. The symptoms 
of TB range from no symptoms (latent TB) to symptoms of active disease. In fact, latent TB is 
not obvious or detectable until a skin test is done, perhaps during a routine test. Symptoms of 
active TB include an overall sensation of feeling unwell, cough possibly with bloody mucus, 
fatigue, shortness of breath, weight loss, slight fever, night sweat and pain in the chest.  
Symptoms of TB can be confused with symptoms of other diseases. Bloody mucus, for 
example, can be an indication of bronchitis or pneumonia.  An evaluation by a doctor is the 
key to confirming whether it is latent, active TB or some other condition. 
1.3       Diagnosis 
Several test methods can be used to detect tuberculosis, depending on the tuberculosis type 
suspected and the resources available for testing. TB disease is recognised by a positive 
tuberculin skin test (TST) result, epidemiologic evidence and a well-matched clinical and 
radiological presentation.25 For years TST was the only test available to diagnose latent TB.   
Lately, the whole blood interferon-gamma release assay (IGRAs) was introduced. The benefit 
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of the new technique over the skin test is that only a visit is required, unlike TST, where two 
visits are essential. 
1.4        Anti-Tuberculosis Chemotherapy 
The prime goal of anti-tuberculosis treatment includes the rapid killing of actively multiplying 
bacilli, prevention of acquired drug resistance, and sterilisation of infected host tissue to 
prevent clinical relapse. One approach to obtaining new antimycobacterial drugs is the 
development of new molecules by modifying old drugs with the aim to improve the 
antimycobacterial activity and to obtain better resistance profiles, availability and tolerability, 
among others.26  
The first-line anti-TB drugs, usually administered at the onset of the disease, are isoniazid, 
rifampicin, streptomycin and pyrazinamide.27 These drugs are effective, but the problem is that 
the bacterium often develops drug resistance because of spontaneous genetic mutations 
involving the molecular targets of the drugs.28 The single-drug-resistant (SDR) and multi-drug 
resistant strains of M. tuberculosis have led to the resort of second-line drugs which are 
ciprofloxacin, ethionamide, kanamycin and p-aminosalicylic acid.29 These drugs, 
unfortunately, have adverse side effects. Hence there is a need for new or modified drugs which 
can overcome bacterial resistance and at the same time have fewer side effects. The WHO aims 
to treat 80% of the MDR-TB cases by 2015. Without unique, simple and inexpensive treatment, 
this is impossible.   
Mycobacteria are organisms that require oxygen to grow (aerobic), non-motile, and they have 
an outer layer.30 The cell wall of Mycobacterium species (Figure 1.2) is very thick, 
hydrophobic, waxy and rich in mycolic acids. The cell wall comprises the hydrophobic 
mycolate layer and a peptidoglycan layer held together by a polysaccharide, arabinogalactan.30 
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The cell wall makes a significant contribution to the rigidity of the bacteria. The biosynthetic 
pathways of cell components are potential targets for new anti-tubercular drugs. 
  
 
Figure 1.2: Schematic representation of the mycobacterial cell wall.31 
 
In the fight against tuberculosis, permeation of chemotherapeutic agents into the cell wall 
remains a severe and major challenge.32 The lipophilic nature of the cell wall makes the 
crossing of hydrophilic molecules difficult, which is a major concern as this can lead to drug 
resistance.32 The directly observed therapy short course (DOTS) developed by the WHO is 
strategised to optimise response and adherence to TB treatment.  The DOT therapy is used for 
the treatment of TB; it is the combination of first-line drugs such as ISO, EMB, RFN and PZA 
prescribed for two months, followed by ISO and PZA for the next 4-5 months.33  The second-
line drugs are considered for the reason that includes route of administration, cost, and 
availability.34   The three broad actions of anti-tuberculosis drugs are bactericidal action, 
sterilising action and prevention of emergence of bacillary resistance to medication.35  The 
mechanisms of these widely used drugs are discussed in the following sections.  
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1.4.1 Isoniazid 
ISO (isonicotinic acid hydrazide) is the current first-line medication that has been the most 
frequently used anti-tuberculosis drug since acknowledgement of its activity in 1952.36 It 
consists of a pyridine ring and a hydrazide group (Figure 1.3). ISO is a nicotinamide analogue, 
structurally related to the anti-tuberculosis drugs ethionamide and PZA. Since it has significant 
bactericidal activity, it has become an important part of the first-line anti-tuberculosis 
regimens, although in the last two decades resistance to ISO has been reported with increasing 
frequency.  
ISO remains a commonly used active first-line agent for the treatment of latent tuberculosis.37 
Its efficacy is more than 90% in latent TB if treatment is completed properly.38  
 
Figure 1. 3: Structure of isonicotinic hydrazide. 
 
1.4.1.1   Mechanism of action 
ISO appears to penetrate host cells rapidly39 and diffuses across the M. tuberculosis 
membrane.40,41 ISO is a prodrug, requiring oxidative activation by the M. tuberculosis catalase-
peroxidase enzyme called KatG.42   It primarily works by inhibiting the formation of mycolic 
acid in the cell wall of M. tuberculosis.  It is active against fast-growing populations of the 
bacteria. 
1.4.2 Rifampicin 
Rifampicin (Figure 1.4) was first isolated in 1957 from Amycolatopsis (formally Streptomyces) 
as part of an Italian screening programme.43,44 It is a much more complicated molecule and is 
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used in conjunction with ISO for active TB.  Their incorporation into the standard anti-
tuberculosis regimen permitted reduction of treatment from 18 to 9 months. Rifampicin is said 
to bind to DNA-dependent RNA polymerase and hinder initiation of RNA synthesis.45  
 
 
Figure 1.4: Structure of Rifampicin. 
 
1.4.2.1 Mechanism of action 
RFN contains an aromatic nucleus linked on both sides by an aliphatic bridge. The rifamycins 
easily diffuse across the M. tuberculosis cell membrane owing to their lipophilic profile.46 They 
are active against bacteria with sprouts metabolism, dominant with irregular short, active 
period of metabolism or growth. Their bactericidal activity has been ascribed to their ability to 
encode DNA-dependent RNA polymerase and inhibit initiation of RNA synthesis. 
1.4.3 Pyrazinecarboxamide 
Since the discovery of pyrazinecarboxamide (PZA, Figure 1.5) in 1952 and its use to treat TB, 
the duration of treatment essential to attain acceptable relapse rates has been reduced from 9-
12 months to the current six months. PZA has bactericidal activity inferior to that of ISO and 
RFN.47 The possible sterilising activity and treatment-shortening potential of PZA are 
attributed to the drug’s exceptional ability to target semi-dominant populations of bacilli 
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present within an acidic environment.48 It is one of the essential medicines needed for basic 
health.49  
 
Figure 1. 5: Structure of Pyrazinecarboxamide. 
1.4.3.1 Mechanism of action 
PZA is a prodrug which inhibits the growth of M. tuberculosis. It is an amide derivative of 
pyrazine-2-carboxylic acid and nicotinamide analogue. PZA diffuses into the granula of M. 
tuberculosis where the pyrazinamidase converts the PZA to the active form pyrazinoic acid. 
The active form of pyrazinoic acid is linked to the disruption of the energetic membrane and 
inhibits membrane transport in M. tuberculosis.50  
1.4.4 Ethambutol 
Ethambutol (EMB; Dextro-2,2-(ethylenediimino)-di-1-butanol) was originally reported to 
have an anti-tuberculosis activity in 1961.51 EMB together with ISO, RFN, and PZA forms the 
modern-day short-course for the treatment of drug-susceptible TB. Like ISO, EMB primarily 
kills actively multiplying bacilli and has poor sterilising activity.52 EMB is a synthetic oral 
antibiotic derivative of ethylenediamine which contains two amine groups and two butanol 
groups (Figure 1.6). 
 
Figure 1.6:  Structure of Ethambutol. 
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1.4.4.1 Mechanism of action 
The primary pathway inhibited by EMB is the synthesis of arabinan in the cell wall of M. 
tuberculosis.53,54 EMB is active against the fast-growing population and mainly used to 
minimise ISO resistance. 
1.4.5 P-aminosalicylic acid (PAS) 
Lehmann discovered p-aminosalicylic acid (Figure 1.7) in 1943. PAS is used primarily as a 
second-line drug to treat MBR TB.55 The emergence of resistance of M. tuberculosis to the 
first-line antibiotics has renewed the interest in second-line anti-tubercular agents. 
 
Figure 1.7: Structure of para-aminosalicylic acid. 
 
1.4.5.1 Mechanism of Action 
PAS is thought to inhibit folic acid biosynthesis, and uptake of iron.56   PAS inhibits the growth 
of tubercle bacilli by impairment of folate synthesis and inhibition of iron absorption.57 It is 
bacteriostatic against M. tuberculosis.58 
1.5.1 Problems of Present Anti-Tubercular Drugs 
There are several major problems related to the presently existing TB treatments, in the first 
instance the length of time and complexity of therapy resulting in nonadherence to treatment. 
This leads to suboptimal response, the advent of resistance and continuous spread of the 
disease.59 Secondly, the contrary events in response to anti-TB drugs are common and 
contribute to the problem of nonadherence.60 The third problem is the increasing incidence of 
multidrug-resistance (MDR; resistance to at least RFN and ISO) and extensive drug-resistance 
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(XDR; MDR resistance plus resistance to a fluoroquinolone and an aminoglycoside).61  
Fourthly, coinfection of TB and HIV is a problem by itself.62-64 The joint treatment of TB and 
HIV involves the use of drugs with related adherence difficulties and overlying toxicity 
profiles.65,66 Obviously, there is a crucial need to improve the existing drugs or introduce new 
drugs. Possible new drugs should decrease treatment time and have satisfactory tolerability 
profile.  
1.5.1.1 Nanoparticles in Anti-TB Delivery: 
A literature review outlining the problems in assessing the treatment and adherence towards 
anti-TB therapy reports that the patient compliance to the current multi-drug regimen is poor 
and this leads to the further progression of the disease condition.67 The lack of compliance is a 
result of the prolonged treatment period and high daily dose count which also increase the drug-
related toxicity. One of the major ways to achieve good compliance rate is either to reduce the 
overall period of drug usage or to simplify the daily pill count. Compliance can be 
accomplished by incorporating sophisticated formulation techniques. Encapsulating the anti-
TB drugs within microparticles or nanoparticles can significantly enhance the bioavailability 
of the drugs and thereby reduce the frequency of the administration. This type of drug 
encapsulation acts as a drug reservoir and slowly releases the drug over a prolonged period.67 
1.5.1.2 Immune-Modulator in TB Therapy: 
In several other bacterial infections, the period necessary to treat the disease is comparably less 
because once the drug initiates the killing of the bulk of the bacilli, the host immune system 
can take care of the remaining bacilli. The reverse is the case in TB bacteria. The TB bacteria 
weaken the host immune system.68 There are some well-known TB antigens which can 
influence the host immune system69,70 and thereby make it incapable of fighting off residual 
bacteria on its own. To avoid this situation, the incorporation of immune-modulators in the 
treatment regime for TB seems to be a logical option. 
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1.6 Transition metal complexes in medicine 
Metal ion plays an important role in biology and has led to the development of a huge number 
of metal complexes with various therapeutic activities. The developments in the field of 
chemistry provide better opportunities to use metal complexes as therapeutic agents. Metal 
complexes have shown promising outcomes in the treatment of diseases like diabetes, 
ulceration, rheumatoid arthritis and inflammatory and cardiovascular diseases.71 
 
1.7 Aim of the Present Research 
This aim of this project was to develop metal complexes of anti-tubercular drugs that have 
enhanced membrane permeability relative to the parent drugs and hence possibly higher 
bioavailability and thus be more effectual against resistant TB strains. 
1.8 Objectives  
The objectives were as follows: 
• To study metal complex equilibria using glass electrode potentiometry. 
• To determine the structures of the complexes in solution using UV-Vis spectroscopy. 
• To measure the lipophilicity and hydrophilicity of the complexes using octanol/water  
partition coefficients. 
• To assess the permeability of metal complexes using Franz cell diffusion 
measurements. 
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• To establish the structures of the metal complexes in the solid state using a variety of 
techniques (elemental analysis, FTIR spectroscopy, single crystal and powder X-ray 
diffraction).  
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2.0 Transition metal complexes as potential therapeutic agents: 
Transition metals have a crucial place within medicinal biochemistry.  Research has revealed 
outstanding progress in the application of transition metal complexes as drugs to treat several 
human diseases like carcinomas, lymphomas, diabetes and neurological disorders.  Transition 
metals exhibit variable oxidation states and can interact with several negatively charged 
molecules.  This activity of transition metals started the progress of metal-based drugs with 
promising pharmacological application and may offer exceptional opportunities.  Coordination 
of metal cations with organic drugs is a promising approach that has been successful in many 
cases with different pharmacological activities.1-6 Specifically, several metallic complexes of 
anti-tubercular drugs have been reported, but accounts of studies of the solution state as well 
as the solid state of such complexes, to improve the permeability and bioavailability of the 
parent drug, are lacking. 
2.1 Metal ion complexes of anti-TB agents 
Complexation between anti-tubercular drugs and metal ions and the methods for complex 
synthesis have been reported by different authors.  Allan et al.7 reported some first-row 
transition metal complexes of ISO. Complexes of the chlorides and bromides of manganese(II), 
cobalt(II) and nickel(II), copper(II) and zinc(II) with ISO have been prepared and studied using 
magnetic susceptibilities, infrared and electronic spectra. 
Cole and co-workers8 have investigated copper (II) and zinc (II) interaction with ISO. The 
formation constants for copper (II) and zinc (II) complexes of ISO and guanosine-5-
monophosphate have been measured potentiometrically at 37 °C, I =150 mmol dm-3 [NaCl]. 
These constants have been used in computer models to assess the extent of complex formation 
by the drug in vivo. 
21 
 
Sousa et al.9 have described ISO metal complex reactivity and insight for the development of 
a novel anti-tuberculosis drug design.  Reactivity studies were conducted with hydrogen 
peroxide, hexacyanoferrate(III), and aqua penta cyanoferrate(III).  The latter species showed a 
preference for the inner-sphere electron transfer reaction pathway. Additionally, the electron 
transfer reaction performed with either free ISO or (ISO) penta cyanoferrate(II) complex 
resulted in similar oxidised ISO derivatives as seen when KatG enzyme was used.  However, 
upon metal coordination, a significant enhancement in the formation of isonicotinic acid was 
observed as compared with that of isonicotinamide.  
 Buss et al.10 reported the oxidation of antibiotic RFN catalysed by a metal ion.   The metal 
ions Cu(II), Mn(II) and Co(II), catalysed the oxidation of RFN from naphthol hydroquinone to 
the naphthoquinone form.  Several transition complexes possess anti-tubercular properties and 
because these complexes often pose stronger activity than the parent compound, it was 
hypothesised that the active form of most anti-tubercular drugs is in fact the metal complex 
itself. 
Thakar et al.11 studied the interaction of transition metal ions and rare earth metal ions with 
drug ISO in 20% (v/v) ethanol-water mixture at 0.1 (NaClO4) ionic strength and a temperature 
of 298 K by potentiometric titration.  The data obtained were used to calculate the values of 
proton-ligand stability constant (pK) and metal-ligand stability constant (log K).  The transition 
metal ions and rare earth metal ions form 1:1 and 1:2 metal-ligand complexes. 
Magare and co-workers12 reported the interaction of some anti-tubercular drugs with transition 
metal ions.  The stability constants of Mn(II), Co(II), Ni(II), Cu(II), and Zn(II) complexes with 
PZA, ISO and EMB-HCl were evaluated. The study was carried out at 30 °C and fixed 0.1 M 
(NaClO4) ionic strength in an aqueous medium potentiometrically.  The proton-ligand stability 
constants and metal-ligand stability constants were determined and discussed with respect to 
22 
 
the order of stability and the basicity of ligands, and correlated with atomic number, ionisation 
potential, electronegativity and reciprocal of ionic radii. 
Shailendrasingh et al.13 examined the stability constants for complexation of ISO and 
imipramine hydrochloride with transition metal ions Fe, Co, Ni, Zn and Cd by potentiometric 
titration in 20% (v/v) ethanol-water mixture at three different temperatures (25 °C, 35 °C and 
45 °C) and an ionic strength of 0.1 M NaClO4.  The method of Calvin and Bjerrum as adopted 
by Irving and Rossetti has been employed to determine metal-ligand stability constant log K 
values.  The transition metal ion forms 1:1 and 1:2 complexes. The thermodynamic parameters 
such as Gibbs free energy change (∆G), entropy change (∆S) and enthalpy change (∆H) 
associated with the free complexation reactions were calculated.  The formation of metal 
complexes was found to be spontaneous, exothermic in nature and favourable at a lower 
temperature. 
Nageswara et al.14 studied the protonation and complexation equilibria of EMB-HCl 
potentiometrically in an aqueous medium at an ionic strength of 0.1 mol dm-3 and 303 K.  The 
protonation constants, as well as binary stability constants of Cu(II), Ni(II) and Co(II) 
complexes, were evaluated, and the best fit was chosen based on the statistical parameters using 
the MINIQUAD75 computer program. 
 Shehata et al.15 investigated the thermodynamics of metal complexation of the macrocyclic 
antibiotic RFN.  The stoichiometric equilibrium constants were determined in 50% (v/v) 
methanol-water medium at different temperatures and constant ionic strength (0.05 M KCl) by 
means of potentiometry. 
Yamabe et al.16 have shown that metal complexation of drugs changes their bioavailability and 
toxicity.  Oliveira et al.17 studied the Co(III) complexes of thiosemicarbazones as potential 
anti-M. tuberculosis agents.  Co(II) complexes from 2-acetyl pyridine N (4)-R-
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thiosemicarbazone (Hatc-R, R=alkyl, aryl) have been characterised by elemental analysis, 
FTIR, UV-Visible and 1H NMR spectroscopies, cyclic voltammetry, conductimetry 
measurement and single crystal X-ray diffraction.  The Co(III) complex showed satisfactory 
activity with minimal inhibitory concentration value under 10 µmol dm-3 and presented quite 
low toxicity. 
Sonar and Pawar18 investigated the spectroscopic and pH-metric studies of Ce(III), Dy(III), 
Gd(III), Yb(III), and Pr(III) metal complexes of RFN.  The metal-ligand and proton-ligand 
stability constants were determined at various ionic strengths.  The calculated values of the 
stability constants are high, indicating stable complexes over a wide range of ionic strength.     
Sonar and Pawar19 determined the stability constants of rifampicin complexes with rare earth 
metal ions in the temperature range 303-318 K at constant ionic strength 0.1 M in 50% dioxane-
water mixture using the pH-metric technique.  The thermodynamic parameters (∆G, ∆H and 
∆S) were calculated. The formations of the metal complexes were found to be spontaneous and 
exothermic in nature. 
Bilgic Alkaya et al.20 studied the ternary complex formation of ISO with some transition metals 
and amino acids using spectroscopy and potentiometric techniques.  Their stability constants 
were determined and the results showed that forming ternary complexes of ISO –metal with 
amino acids can increase anti-tumor activity. The presence of Zn(II) and Cu(II) balances and 
prevents hepatic toxicity as well as side effects.  Copper and zinc bonding geometry are square-
planar with ISO carbonyl oxygen and hydrazide amino nitrogen atom donors.  Complexing 
with Cu(II) and Zn(II) does not significantly alter ISO molecular conformation. 
Patel et al.21 synthesised Cu(II), Ni(II) and Co(II) complexes of ciprofloxacin and evaluated 
their antimicrobial, antioxidant and anti-tubercular activity.  It was observed that the anti-TB 
activity of the ligand was enhanced on complexation with Ni(II) and Co(II) ions. 
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Tiwani22 reported the antibacterial activity of mixed ligand chelate and its application to 
tuberculosis. The study revealed that metal chelates (complexes) are more potent compared to 
the parent drug. 
Sandbhor et al.23 worked on metal complexes of carboxamidrazone analogues as anti- 
tubercular agents; the analogues were synthesised, and the structures of their metal complexes 
were determined using X-ray crystallography. All complexes were assessed for their in vitro 
activity upon copper complexation, resulting in enhancement factors of 32-64 in their anti-
tubercular activity.  
Phase et al.24 determined the stability constant of the ternary chelate of Zn(II) metal ion with 
aspartame and EMB-HCl as first ligand and amino acid as a secondary ligand.  The reaction 
was carried out in 20% (v/v) ethanol-water medium pH-metrically at 30 °C and 0.1 M NaClO4 
ionic strength.  The formation of complex species as a function of pH was also discussed using 
the method of Irving and Rossotti and evaluated using the computer SCOGS program. 
Anti-tubercular drugs can coordinate with metal cations through different chemical groups: in 
the case of ISO, these are the heterocyclic nitrogen from the pyridine ring, the carboxylic O 
atom and N atoms of the hydrazide group.  For this versatility, ISO is also an interesting ligand 
from the chemical point of view.  The d-block elements form small, highly-charged, ions with 
vacant, low energy orbitals which are able to accept lone pairs of electrons donated by ligands 
and this favours metal complex formation.25   The drugs ISO, EMB, PZA and PAS are all able 
to act as ligands and form metal complexes.   Hence, these are good targets for investigation. 
The stability of metal complexes of therapeutic drugs plays a major role in biological processes 
in the context of metalloproteins, metalloenzymes, storage, transport, detoxification and 
chemical activity.26,27  
 
25 
 
References:     
 
1. L. R. Azuara and M. E. Bravo-Gomez, Curr. Med. Chem., 2010, 17, 3606-3615. 
2. World Health Organization, TB.  Global Emergency, WHO Report No.14977, Geneva, 
Switzerland, 1994, 97-98. 
3. B. Bottari, R. Maccari, F. Monforte, R. Ottana, E. Rotondo and M. G. Vigorita, Bioorg. 
Med. Chem. Lett., 2000, 10, 657-660.  
4. G. Lowe, A. S. Droz, T. Vilaivan, G. W. Weaver, J. J. Park, J. M. Pratt, L. Tweedale 
and L. R. Kelland, J. Med. Chem., 1999, 42, 3167-3174. 
5. R. A. Sanchez-Delgado, M. Navarro, H. Perez and J. A. Urbina, J. Med. Chem., 1996, 
39, 1095-1099. 
6. R. Malhotra, J. P. Singh, M. Dudeja and K. Sdhindsa, J. Inorg. Biochem., 1992, 46, 119-
127. 
7. J. R. Allan, G. M. Baillie and N. D. Baird, J. Coord. Chem., 1984, 13, 83-88. 
8.  A. Cole, P. P. May and D. R. Williams, Agent Actions,1993, 13, 91-97. 
9. E. H. Sousa, L. A. Basso, D. S. Santo, I. C. Diogenes, E. Longinotti, L. G. Lopes and I. 
S. Moreira, J. BioInorg. Chem., 2012, 17, 275-83. 
10. W. C. Buss, E. Reyes and T. D. Barela, Res. Commun. Chem. Pathol. Pharmacol., 1977, 
17, 547-50 
11. S. V. Thakar, M. Farooqui and S. D. Naikwade, Int. J. Inorg. Chem., 2012, 4, 5-7. 
12. B. K. Magare, M. N. Farooqui, R. S. Shelke, and M. B. Ubale, Orient. J. Chem., 2009, 
25, 387-390. 
13. V. T. Shailendraingh, F. Mazahar and D. N. Sahebra, J. Chem., Biol. Phys. Sci., 2013, 
4, 1-7. 
14. G. R. Nageswara and M. M. Annapurna, J. Pharm. Educ. Res., 2010, 1, 44-50. 
26 
 
15.  I. Shehata, I. Kenawy, A. H. Askalany and A. A. Hassan, Can. J. Chem., 2001, 79, 42-
49. 
16. S. Yamabe and K. T. Tokyo, Chem. Abs., 1989, 111, 219307z.  
17. C. G. Oliveira, P. I. Maia, M. Miyata, F. R. Pavan, C. Q. F. Leite, E. T. Almeida and V. 
M. Teflon, J. Braz. Chem. Soc., 2014, 25, 1848-1856. 
18. A. N. Sonar and N. S. Pawar, E-J Chem., 2011, 8, 517-522. 
19. A. N. Sonar and N. S. Pawar, J. Chem. Pharm. Res., 2010, 2, 446-449. 
20. D. B. Alkaya, S. Karaderi and G. Erdogan, Trakya Univ. J. Nat. Sci., 2013, 14, 1-14. 
21. K. S. Patel, J. C. Patel, H. R. Dholariya, V. K. Patel and K. D. Patel, Open J. Met., 2012, 
2, 49-59. 
22. C. R. Tiwari, Pharma. Chem., 2012, 4, 39-42. 
23. U. Sandbhor, S. Padhye, D. Billington, D. Rathbone, S. Franzblau, C. E. Anson and A. 
K. Powell, J. Inorg. Biochem., 2002, 90, 127–136. 
24. R. P. Phase, A. G. Shankarwar, S. G. Shankarwar and T. K. Chondhekar, Adv. App. Sci 
Res., 2013, 4, 46-49. 
25. J. Chen, K. Fukuzumi, B. Lp, Florence and A. P. Cid, Int. J. Pharma. Biol. Chem. Sci., 
2014, 3, 36-45. 
26. L. Oehninger, R. Rubbiani and I. Ott, Dalton Trans., 2013, 42, 3269-84. 
27. S. Thakar, S. Naikwade and M. Farooqui, Int. J. Chem. Sci., 2013, 1, 88-92. 
 
 
 
 
27 
 
 
Chapter 3 
 
Glass Electrode Potentiometry  
  
28 
 
3.1 Glass Electrode Potentiometry 
Glass electrode potentiometry (GEP) is a volumetric method in which the potential difference 
between two electrodes (reference and indicator electrode) is measured as a function of the 
added reagent. It is the most versatile and frequently used analytical technique for studying 
chemical interaction in aqueous solution.1 The difference in potential (emf) is used to measure 
the concentration of the analyte. 
The main advantage of this technique, compared to other methods, is the possibility of 
monitoring the resulting complexation as a function of pH and to observe the exact point at 
which complexation takes place.  Also, the dissociation constants and the stability constants of 
complexes can be calculated.2 This method requires the use of a glass hydronium ion selective 
electrode (indicator electrode), an appropriate reference electrode and a sensitive 
potentiometer.3,4   
There are factors which assist the formation of a complex.  The capacity of a metal ion to form 
a complex with a ligand is decided by its environment which in turn decides the stability of the 
compound. Some of the factors which affect the stability of the complexes are solvents, 
temperature, nature of metal ion and nature of ligands. 
In this study, glass electrode potentiometry was used to investigate the interaction between the 
ligand, the protons and the metal ions.  Potentiometric data were analysed using the 
Equilibrium Simulations for Titration Analysis (ESTA) suites of the program.  These data were 
also used to envisage the possible metal/ligand models and to predict the distribution of species 
in solution. 
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3.2 Theory 
The theory of formation constant and methods of determination has been covered extensively 
in the literature.5-7 
For the reaction 
                                   𝐿 + 𝐻 ⇌ LH  
where L is the ligand, H is a proton and LH is a protonated ligand, the thermodynamic 
protonation constant, TK, of the ligand can be expressed as 
                                                 TKLH  =
{𝐿𝐻}
{𝐿} {𝐻}
        (3.1) 
where {LH} is the activity of the singly protonated ligand, {L} is the activity of the ligand and 
{H} is the activity of the proton. 
Likewise,  
                                     {X}  = 
𝑋
[ X ]        (3.2) 
where{X} is the activity of species X (which can be a ligand, a proton or a metal ion), x is the 
activity coefficient of the species X and [X] is the molar concentration of X. 
Therefore, 
                                             TKLH = 
(𝐿𝐻[𝐿𝐻])
(𝐿[𝐿])(ϒ𝐻[𝐻])
       (3.3) 
Equation (3.3) can be rearranged as     
                   TKLH     = (
𝐿𝐻
𝐿𝐻
) (
[𝐿𝐻]
([𝐿][𝐻])
)       (3.4) 
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At constant ionic strength (
𝐿𝐻
𝐿𝐻
)  is constant and the equilibrium constant can be expressed as                    
                       KL1 = 
[ LH ]
[L][H]
         (3.5) 
For a ligand that has three protonation constants, TKL1, 
TKL2 and 
TKL3, these can be described 
in a stepwise manner as 
                     L + H ⇌ LH                                                                  KL1 = 
[LH]
[L][H]
   (3.6) 
                     LH + H ⇌ LH2                                                            KL2 = 
[LH2]
[LH][H]
   (3.7) 
                     LH2 + H ⇌ LH3                                                             KL3 = 
[LH3]
[LH2][H]
   (3.8) 
Also, for the ligand with n protonation constants 
                  LHn-1 + H ⇌ L𝐻𝑛                           KLn    = KL1 KL2 KL3…Ln = 
[𝐿𝐻𝑛]
[𝐿𝐻𝑛−1][𝐻]
   (3.9) 
Similarly, for the metal M and the ligand L that react to give a complex ML, the stability 
constant (KML) can be described as 
                   M + L ⇌ ML                                                                  KML1 = 
[ML]
[M][L]
   (3.10) 
                  ML + L ⇌ ML2                                                              KML2 = 
[𝑀𝐿2]
[ML][L]
   (3.11) 
Therefore, for the general case,  
                  MLn-1 + LH ⇌ MLn + H                                         KMLn = 
[𝑀𝐿𝑛][H]
[𝑀𝐿𝑛−1][LH]
  (3.12) 
The overall formation constant, β can be expressed as 
                 L + H ⇌ LH                                                             βLH  =  KLH1 = 
[LH]
[L][H]
  (3.13) 
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                 LH + H ⇌ LH2                                            βLH2    = KLH KLH2 = 
[𝐿𝐻2]
[𝐿𝐻][𝐻]
    (3.14) 
                LH2 + H ⇌ LH3                               βLH3    = KLH KLH2 KLH3 = 
[𝐿𝐻3]
[[LH]2][H]
     (3.15) 
                LHn-1 + H ⇌ LHn              β LHn     = KLH KLH2 KLH3…LHn = 
[𝐿𝐻𝑛]
[𝐿𝐻𝑛−1][H]n   
   (3.16) 
Similarly, 
               M + L  ⇌ ML                                                      βML1    =   KML1= 
[ML]
[M][L]
         (3.17) 
              ML + L ⇌ ML2                                            βML2    =   KML1KML2 = 
[ML2]
[ML][L]
     (3.18) 
and           
            MLn-1 + L ⇌ MLn                   KMLn = KML1KML2 KML3𝐾𝑀𝐿𝑛 = 
[𝑀𝐿𝑛]
[𝑀𝐿𝑛−1][𝐿]𝑛
    (3.19) 
For the reaction 
                          pM + qL + rH ⇌ MpLqHr 
p, q and r represent the stoichiometric coefficients of M, L and H respectively, r the 
stoichiometric coefficient of H or hydroxyl ion added to the complex. The formation constant 
(β) of the reaction can be expressed as 
                             𝛽𝑝𝑞𝑟
[𝑀𝑝𝐿𝑞𝐻𝑟]
[𝑀]𝑝[𝐿]𝑞[𝐻]𝑟
                                                                                          (3.20) 
The concentration of MpLqHr at point k is expressed as 
                             [MpLqHr]k   = βpqr[M]kp[L]kq[H]kr                                                                               (3.21) 
The total concentration of the metal ion at point k (TM, K) can be expressed as  
𝑇𝐾,𝑀 = [𝑀]𝐾 + ∑ 𝑃 𝛽𝑝𝑞𝑟[𝑀]𝑝
𝑘
𝑁
𝑖=1
[𝐿]𝑞
𝑘[𝐻]𝑟
𝑘                                                                                 (3.22) 
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The total concentration of the ligand at point k (TL, K) can be expressed as 
𝑇𝐾,𝐿 = [𝐿]𝐾 + ∑ 𝑃 𝛽𝑝𝑞𝑟[𝑀]𝑝
𝑘
𝑁
𝑖=1
[𝐿]𝑞
𝑘[𝐻]𝑟
𝑘                                                                                           (3.23)       
The total concentration of the hydronium ion at point k (TH, K) can be expressed as 
𝑇𝐾,𝐻 = [𝐻]𝐾 + ∑ 𝑃 𝛽𝑝𝑞𝑟[𝑀]𝑝
𝑘
𝑁
𝑖=1
[𝐿]𝑞
𝑘[𝐻]𝑟
𝑘                                                                                    (3.24) 
                     
The coefficient of the proton (r) can be greater than or equal to 1 if the complex is protonated. 
However, if the ligand loses all its protons upon complexation with the ligand, or if the 
hydroxide ion (OH-) is added to the complex, then r can have a negative value.8,9   When the 
complex is not protonated, and there is no hydroxide ion attached to the complex then r = 0. 
ML, MLH, MLH2 and MLHn indicate a complex with one central metal ion that is not 
protonated, singly protonated, doubly protonated, and having one ligand and n protons attached 
respectively. 
3.3 Data Analysis  
The stability constants of the protonation/deprotonation of the ligands and complexes were 
calculated from the potentiometric data using the ESTA suite of programs.  This package has 
two basic program modules, namely the simulation unit (ESTA1) and the optimisation units 
(ESTA2B). The simulation unit characterises the system on a point-by-point basis, and the 
optimisation unit is used to characterise the titration as giving the average values for the 
titration system. Simulation is done by using the mass balance equations, which help to 
calculate complexation function and speciation of the solution, thereby aiding the interpretation 
33 
 
of the data. ESTA5 is a plotting unit, used to place the results calculated by ESTA1 in a 
graphical form. 
 Three tasks from the ESTA program were used in this study, namely the formation function 
(Z-bar), the deprotonation function (Q-bar) and the objective function (OBJE). 
 The ZBAR task is used to calculate the formation functions at each titration point; the 
calculated and observed functions were obtained from the ZBAR, and the residuals have been 
computed from equations 3.29 and 3.30 for the proton formation functions and the metal 
formation functions respectively. 
                            Residual pH = pHo - pHC      (3.25) 
Similarly 
                           𝑍 − 𝑏𝑎𝑟𝐻 =
𝑇𝐻−𝐻+𝑂𝐻
𝑇𝐿
                                                                                (3.26) 
and 
                            𝑍 − 𝑏𝑎𝑟𝑀 =
𝐴+(𝑛 ∑ 𝐻𝑛𝛽𝐿𝐻𝑛 )
𝑇𝑀
                                                             (3.27) 
 
where                       𝐴 =
𝑇𝐻𝐻+𝑂𝐻
(𝑛 ∑ 𝐻𝑛𝛽𝐿𝐻𝑛 )
                                                                                      (3.28) 
For proton formation function, 
         Residual formation function = Z-baroH – Z-barcH      (3.29) 
For metal formation function, 
         Residual = Z-baroM – Z-barcM                                                                                                                 (3.30) 
where 
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ZH-bar point residual = [(pH
O- pHC)2 + (Z-baroH – Z-barcH)2]1/2                                (3.31) 
and 
ZM-bar = [(pA
O- pAC)2 + (Z-baroM – Z-barcM)2]1/2                                                                              (3.32) 
where pHO  is the observed pH, pHC is the calculated pH,  Z-barOH is the observed proton 
formation constant, Z-barCH the calculated proton formation function, Z-bar
O
M is the observed 
metal formation function, Z-barOM is the calculated metal formation,  pA
O is the negative 
logarithm of the observed ligand concentration, pAC is the calculated ligand concentration, EH 
is the potential of the hydronium ion, and 1EOH is the standard potential. 
SH is the slope of the 
electrode, and log H is the logarithm of the proton concentration. TH is the total concentration 
of the hydronium ion, H is the concentration of the hydronium ion, OH is the concentration of 
the hydroxide ion, TL is the total ligand concentration, A is the ligand concentration, n is the 
number of protons bound to the ligand, βLHn  is the formation constant of the protonated ligand 
with n protons, and TM is the total concentration of the metal ion.
10-12 
The ESTA task Q-bar is used to calculate the observed and calculated deprotonation functions. 
The deprotonation function is defined as the average number of protons released by the ligand 
upon complexation with the metal ion; Q-bar is expressed as 
                    𝑄𝑀 − 𝑏𝑎𝑟 =
(𝑇∗𝐻−𝑇𝐻)
𝑇𝑀
                                                                              (3.33) 
where T*H is the calculated total concentration of protons in the system at the observed pH 
ignoring the presence of all the metal complexes. 
When p = zero and 𝑂𝐻 =
𝐾𝑤
𝐻
 
the mass balance equations for T*H and TL can be written as   
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𝑇∗𝐻 = 𝐻 − 𝑂𝐻 +  ∑ 𝑟[𝑀𝑝𝐿𝑞𝐻𝑟]
𝑁𝐽
𝐽=1
                                                                   (3.34)             
And 
  𝑇𝐿 = 𝐿 + 𝑂𝐻 +  ∑ 𝑞[𝑀𝑝𝐿𝑞𝐻𝑟]
𝑁𝐽
𝐽=1
                                                                         (3.35)                       
where NJ is the total number of titration points. 
For a binary system, a formation function is defined for the ligand subsystem as 
              n-bar =  
𝑇𝐻−𝐻+𝑂𝐻
𝑇𝑟𝐿
          (3.36) 
In general, ZH-bar was used to estimate protonation constants of the ligand and the stability 
constants of the complexes. From ZH-bar, the number of protons bound per ligand was 
estimated, and from ZM-bar the number of protons released by the ligand upon complexation 
with the metal ion was estimated.  Q-bar indicates the number of protons released by the ligand 
on complexation with the metal ion. Q-bar was compared to n-bar which measures the number 
of protons that could have bound to the ligand in the absence of the metal ion. Te distribution 
template of the ESTA programs was used to calculate the distribution of the ligand in the metal 
complexes in solution. 
The formation (ZM-bar) and the deprotonation (QM-bar) functions were used to investigate the 
reproducibility of the experimental data and the reliability of evaluated log βpqr values.13,14 
These two functions serve two purposes. Firstly, they give a visual check on the experimental 
data and secondly, their shape provides an idea of the speciation model applicable to the 
system. 
If the ZM-bar curves at the different metal to ligand ratios are superimposable, then simple 
stepwise complexation is indicated. Non-superposability indicates that polynuclear species are 
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present. Fanning back of ZM-bar curves shows the presence of hydroxo or mixed hydroxo 
species.15 When Q-bar coincides with n-bar, it indicates that no further complexation takes 
place in this range. When Q-bar rises above the n-bar curve, it indicates hydrolysis of the metal 
ion forming species MLH-1. 
The task (OBJE) was used for weighting the objective function (Uobj) contribution based on the 
observed emf and the relative contributions of the most significant errors to the weight at each 
titration point. This function is expressed as; 
                
𝑈𝑜𝑏𝑗 = (𝑁 − 𝑛𝑝)
−1
∑ 𝑛𝑒
−1 ∑ 𝑤𝑛𝑞   (𝑦𝑛𝑞
𝑜𝑏𝑠 − 𝑦𝑛𝑞
𝑐𝑎𝑙𝑐)
2
                            (3.37)
𝑛𝑒
𝑞=1
𝑁
𝑛=1
 
where 
N is the total number of experimental points, np is the total number of points being optimised, 
ne is the total number of electrodes, wnq is the weight of the q
th residual at the nth point and yn
th 
the calculated variable at the qth residual at the nth point. 
Data are optimised by minimising the objective function. This can be achieved if the objective 
function is quadratic with all the parameters (Gauss-Newton method) 
Uobj can, therefore, be expressed as 
                             𝑈𝑜𝑏𝑗 = a + 𝑝𝑡𝑏 +
(𝑝𝑡𝐻𝑝)
2
       (3.38) 
The program also calculates the standard deviations, estimated errors for the parameters being 
optimised using the method of least-squares. The standard deviation σ can be expressed as 
                         σ =     [
𝑈𝑜𝑏𝑗𝐺𝑟𝑟
(𝑁−𝑛𝑝)
]
1/2
        (3.39) 
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The Hamilton R-factor (RH) can be used to test the agreement between the observed and the 
calculated values of the refined data. This factor can be expressed as 
                    𝑅𝑓
𝐻 = [
𝑈𝑜𝑏𝑗
∑ 𝑛𝑒−1 ∑ 𝑊𝑛𝑞(𝑌𝑛𝑞
𝑜𝑏𝑠)2
]
1/2
                                                              (3.40) 
The best possible 𝑅𝑓
𝐻 value based on the number of variables and the random errors in the 
analytical data, 𝑅𝑙𝑖𝑚
𝐻 can be expressed as 
                       𝑅𝑙𝑖𝑚
𝐻 = [
𝑁𝑜𝑏𝑗
∑ 𝑛𝑒−1 ∑ 𝑊𝑛𝑞(𝑌𝑛𝑞
𝑜𝑏𝑠)2
]
1/2
                                                            (3.41)  
If 𝑅𝑓
𝐻 is less than 𝑅𝑙𝑖𝑚
𝐻 the model is within the maximum allowed experimental error.20 
3.3.1 The Electrode Cell  
The electrode cell is the essential tool of potentiometric analysis. An electrochemical cell 
consists of two half-cells, each containing an electrode in contact with an electrolyte. The 
electrode is an electronic conductor, and an electrolyte is a phase in which ions carry charges. 
The half-cells are connected by a salt bridge which allows ions to move between half-cells but 
prevents mixing of the electrolytes. 
The setup of the cell can be represented as below: 
reference electrodesalt bridgeanalyte solutionglass electrode 
    Eref                               Ej                                                  Eg 
Each electrode possesses a half-cell reaction. The reference electrode potential, Eref, has a 
known constant value and it is not affected by the concentration of the analyte solution,16 
whereas the potential of the glass electrode, Eg, varies with the concentration of the analyte 
solution.17 The liquid junction potential, Ej, results from a difference in the concentrations of 
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the analyte solution and the internal reference solution. The observed potential, Ecell, can 
therefore be expressed as 
                                      𝐸𝑐𝑒𝑙𝑙 = 𝐸𝑟𝑒𝑓 + 𝐸𝑗 + 𝐸𝑔                                                                            (3.42) 
As Eg varies with the concentration of the analyte solution, the Nernst equation can be written 
as 
                           𝐸𝑐𝑒𝑙𝑙 = 𝐸𝑟𝑒𝑓 + 𝐸𝑗 +  (𝐸𝑔 +  
𝑅𝑇𝑙𝑛{𝐻}
𝐹
)                                                               (3.43)                                                                                                                        
where Eg is the standard electrode potential and {𝐻} is the activity of the hydrogen ion. 
If the ionic strength and hence the activity coefficient of the H ions are constant, then  
Equation 3.43 can be written as; 
                 𝐸𝑐𝑒𝑙𝑙 = 𝐸𝑐𝑜𝑛𝑠𝑡 +  
𝑅𝑇𝑙𝑛[𝐻+]
𝐹
                                                                              (3.44) 
The potential depends on the temperature, and the relationship between the two varies with the 
activity of the hydrogen ion. This can be expressed in terms of the slope factor, s  
                   𝑠 =
2.303𝑅𝑇
𝐹
                                                                                                    (3.45) 
Substituting Equation 3.45 into 3.44 yields 
               𝐸𝑐𝑒𝑙𝑙 = 𝐸𝑐𝑜𝑛𝑠𝑡 + 𝑠 log[𝐻
+]                                                                              (3.46) 
Both slope, s, and Econst. are determined to calibrate the electrode. 
3.4 Experimental 
3.4.1 Preparation of Solutions 
The potentiometric titrations were performed at a stable temperature and ionic strength18,19 
under an inert atmosphere. The end-point of the potentiometric data and the carbonate 
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contamination of the sodium hydroxide titrant solution were checked by acid-base titration 
using the Gran method.20 The electrode system was calibrated according to the method of 
Irving et al.21   All the solutions used for titration were standardised; the primary chemical of 
known mass was used to standardise the acids/bases which were used to standardise the ligand 
solutions.  Methods for standardisation of solutions of the metal ions are described.22-24 
The chemicals and reagents were of analytical grade and were used without any additional 
purification. Solutions of sodium hydroxide (0.1 M) were prepared from Merck ampoules 
(1.09959-Trisol) in distilled deionised water and were prepared under an inert atmosphere of 
nitrogen gas to eliminate any contamination by CO2. These solutions were standardised against 
potassium hydrogen phthalate (KHP). The solutions of hydrochloric acid (HCl) (0.01 M) were 
prepared from Merck ampoules (1.09970) and standardised with the standard solution of 
sodium hydroxide using Gran methods. All stock solutions were prepared using NaCl as a 
background electrolyte to maintain a constant ionic strength of 0.15 mol dm-3. 
The ligands were purchased from Sigma-Aldrich (South Africa). They were in powder form 
and were 99.0% pure. 0.01 M Ligand solution was prepared in 0.01 M HCl. The metal solutions 
were prepared by dissolving NiCl2.6H2O, CuCl2.2H2O and ZnCl2 in boiled out glass distilled 
water to yield 0.01 M solutions. The toxic level of the metals was considered by using a low 
concentration of metal. 
The choice of the metal ions rests on their availability and on their importance in a 
physiological system. They were standardised by using a meter ohm 765 Dosimat automatic 
burette dispensing 0.01 mol dm-3 EDTA solution. Titration was done in duplicate to check the 
reproducibility.  
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3.4.2 Potentiometric Measurement 
All pH measurements were carried out at 25 °C and a stable ionic strength of 0.15 mol dm-3 
(NaCl). The Ω Metrohm glass electrode was calibrated with a set of Ω Metrohm ion analysis 
pH buffers, and the Nernstian slope was determined.25,26 The slope varied from 57.13 to 58.27 
and the pH range from 2.00-11.00 using a Ω Metrohm 848 Titrino plus. The data of acid/base 
titrations were used to calculate the electrode response intercept, EO, from the slope and the 
negative logarithm of the water ion product, pKw.  
For the protonation of the ligand, an exact volume was taken from the prepared ligand solution.   
The solution was stirred continuously and gently with a Ω Metrohm 801 magnetic stirrer. When 
a stable temperature of 25 ± 0.1 °C was attained, the solutions of the ligands were titrated with 
standard solutions of sodium hydroxide.  For the complexation titration, the metal to ligand 
molar ratios varied between 1:1 and 1:2.  These solutions were titrated with standard solutions 
of NaOH.  
3.5 Results     
3.5.1 Isoniazid (ISO) 
3.5.1.1 Protonation 
 ZH-bar for protonation of ISO is presented in Figure 3.1. The function levels to zero at a high 
pH of 11.82; thereafter, it rises and then levels off at the ZH-bar value of 1 between pH 9.38 
and 5.57. Below pH 4.78 the function rises to a ZH-bar of 1.8.  This indicates that two protons 
have been added to the ligand making it di-protonated at low pH. 
Protonation constants of ISO were estimated from the half ZH-bar values, log KLH1 of 10.95, 
log KLH2 of 3.67, and these values were used as the starting values in ESTA. 
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Figure 3.1: ZH-bar as a function of pH for the protonation of ISO. 
 
Optimised log pqr are given in Table 3.1. The results are in good agreement with literature 
values of log KLH1 of 10.6 and log KLH2 of 3.8 for ISO at 25 °C and I = 0.10 mol dm
-3.27 The 
theoretical and experimental plots are shown in Figure 3.1. They are well superimposed, and 
this gives confidence to the result. 
Table 3.1 : Stability constants (log βpqr) for ISO βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol dm-3 (NaCl), 
T = 25 °C. S. dev. denotes standard deviation in log βpqr; 𝑅𝑓
𝐻 is the Hamilton R-factor and  
𝑅𝑙𝑖𝑚
𝐻  its limit, nT is the number of titrations, (nP) is the number of titration points. 
 
Ligand P q R log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
ISO-H 
 
ISO-H2 
0 
 
0 
 
1 
 
1 
 
1 
 
2 
 
10.95 
 
14.62 
 
0.003 
 
0.003 
 
 
 
0.003 
 
 
0.001 
 
 
2(323) 
 
 
The three species of this ligand are shown in the speciation graph in Figure 3.2. The 
predominant species in solution from pH 3.77-9.36 is LH.   
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Figure 3.2: Distribution curve for the protonation of ISO. 
 
The protonation of ISO is through both the pyridyl nitrogen and the hydrazide group. The 
measured dissociation constants for ISO of 3.67 and 10.95 correspond to the protonation of the 
pyridine nitrogen and the hydrazide group respectively. The values obtained are close to the 
literature values of 10.6 and 3.8,27 and 10.8 and 3.5.29 
3.5.1.2 Copper complexation 
Figure 3.3 shows the complex formation (ZM-bar) for the Cu(II) ISO titrations. The ZM-bar 
function levels off at ~ 0.4, indicating that ML is not the predominant species in the solution.  
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Figure 3.3: ZM-bar as a function of pA for Cu(II) ISO complex. 
 
The deprotonation function (QM-bar) in Figure 3.4 shows that at a pH of approximately 2.91, 
the Q-bar is greater than zero indicating that complexation has commenced. ISO has two 
dissociable protons, and it loses one upon complexation with Cu(II). 
 
Figure 3.4: QM-bar as a function of pH for the Cu(II) ISO complex. 
 
The reproducibility of repeat titrations and excellent agreement, at different metal to ligand 
ratios, between the theoretical and experimental formation and deprotonation function curves 
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gives confidence to the result. The stability constants are given in Table 3.2. The stability 
constant log K of 6.52 has been reported in literature for the CuISO complex at 30 °C and I= 
0.10 M NaClO4.
30 The standard deviation is reasonably low. The Hamilton 𝑅𝑓
𝐻 factor indicates 
that the model is a good description of the equilibria occurring in solution.  
Table 3.2: Stability constants (log βpqr) for Cu(II) ISO βpqr = [MpLqHr]/[M]p[L]q[H]r, I=0.15 mol dm-3 
(NaCl), T = 25 °C. S. dev. denotes standard deviation in log βpqr; 𝑅𝑓
𝐻  is the Hamilton R-factor and 𝑅𝑙𝑖𝑚
𝐻  
its limit, nT is the number of titrations, (nP) is the number of titration points. 
 
Complexes P q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
CuISOH 
 
CuISO 
  
1 
 
1 
 
 
1 
 
1 
 
 
 1 
 
0 
 
 
13.77 
 
8.98 
0.007 
 
0.009 
 
 
0.009 
 
 
0.003 
 
 
5(200) 
The speciation graph for Cu(II) ISO is given in Figure 3.5.  Only MLH and ML species are 
formed, MLH being the more stable species. Formation of precipitate was observed at pH 
above 4.8. 
 
Figure 3.5: The distribution curve for the Cu(II) ISO complex (metal to ligand ratio 1:1). 
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3.5.1.3 Nickel complexation  
 ZM-bar for Ni(II) ISO as a function of pA is given in Figure 3.6.  Note that this curve is very 
different from the one obtained with Cu(II). The main reason for this is the pH.  In the case of 
Ni(II), the titration could be continued to pH 11, whereas with Cu(II) precipitation occurred 
above pH 5. The hump at pA 10 indicates the presence of a protonated species, while the 
fanning back at pH 4.9 is indicating the formation of hydroxy species.  ISO has two dissociable 
protons, but one was lost upon complexation with Ni(II) (Figure 3.6).  
  
 
Figure 3.6: ZM-bar as a function of pA for Ni(II) ISO complex. 
 
The deprotonation function QM-bar for Ni(II) ISO complex is shown in Figure 3.7. At pH 5-7 
the Q-bar levels off at zero indicating that no further complexation takes place in this pH range. 
The bar rises above n-bar in the pH range of 8.9 and 9.9 indicating the formation of the hydroxo 
species. 
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Figure 3.7: QM-bar as a function of pH for Ni(II) ISO complex. 
Species formed between Ni(II) and ISO and their stability constants are given in Table 3.3. The 
reproducibility of the titration results and agreement between the theoretical and experimental 
formation and deprotonation functions at the different metal to ligand ratios gives confidence 
to the model. A stability constant log K of 5.11 has been reported in literature for the NiISO 
complex at 30 °C and I = 0.10 M NaClO4.
30 
Table 3.3: Stability constants (log βpqr) for Ni(II) ISO complex βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 
mol dm-3 (NaCl), T = 25 °C. S. dev. denotes standard deviation in log βpqr;  
𝑅𝑓
𝐻 is the Hamilton R-factor and 𝑅𝑙𝑖𝑚
𝐻  its limit, nT is the number of titrations, (nP) is the number of 
titration points. 
 
Complexes P q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
NiISOH 
 
NiISO 
 
NiISOH-1
  
1 
 
1 
 
1 
1 
 
1 
 
1 
1 
 
0 
 
-1 
12.92 
 
4.92 
 
-4.04 
0.02 
 
0.01 
 
0.01 
 
 
0.015 
 
 
0.003 
 
 
5(146) 
 
Figure 3.8 shows the speciation graph for 1:1 Ni(II) ISO in the pH range of 2.0 to 11. The MLH 
species forms in the pH range 2.1 to 9.8 and a maximum of 61% was observed, while ML forms 
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between pH 6.6 and pH 9.2 and reached a maximum of 63%. About 96% of MLH-1 was 
established between pH 7.8 and 10.5. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: The distribution curve for the Ni(II) ISO complex (metal to ligand ratio 1:1). 
 
3.5.1.4 Zinc complexation  
 ZM-bar as a function of pA is shown in Figure 3.9. The complexation curves for various metal 
to ligand ratios start at pA= 6.7. The formation function rises and fans back, thus indicating the 
formation of hydroxyl complex species in solution. The agreement between the theoretical and 
experimental complex formation curves at the different metal to ligand ratios support the 
potentiometric model chosen in data analysis. 
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Figure 3.9: ZM-bar as a function of pA for Zn(II) ISO complex. 
QM-bar for Zn(II) ISO titration is depicted in Figure 3.10. At pH 3.31 the deprotonation function 
value of zero indicates that no protons have been displaced due to complexation. For pH values 
above 6.36, the deprotonation function Q-bar rises to intersect the protonation curve, n-bar, at 
a pH of 7.75, reaching a maximum of about 1.09.  ISO has two dissociable protons, and it loses 
one proton upon complexation with Zn(II). The system consists mostly of hydroxo species 
from pH 7.7 to pH 10.1.      
 
 
Figure 3.10: QM-bar as a function of pH for Zn(II) ISO complex. 
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Table 3.4 shows that two species were obtained in the complexation of Zn(II) with ISO and 
their stability constants are shown. The standard deviations of the log βpqr values obtained from 
the potentiometry are reasonably low. A stability constant log K of 5.71 has been reported in 
literature for the CuISO complex at 30 °C and I = 0.10 M NaClO4.
30 
Table 3.4: Stability constants (log βpqr) for Zn(II) ISO complex βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 
mol dm-3 (NaCl), T = 25 °C. S. dev. denotes standard deviation in log βpqr; 𝑅𝑓
𝐻  is the Hamilton R-factor 
and 𝑅𝑙𝑖𝑚
𝐻  its limit, nT is the number of titrations, (nP) is the number of titration points. 
 
Complexes P q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
ZnISO 
 
 
ZnISOH-1 
 
1 
 
1 
 
 
1 
 
1 
 
 
0 
 
1 
 
 
5.50 
 
-2.10 
 
0.03 
 
0.01 
 
 
 
 
0.02 
 
 
0.005 
 
 
4(118) 
 
Figure 3.11 shows the distribution of the three species of the ligand from pH 2.2 to 10.2. 40% 
of Zn(II) existed in ML form at pH 7.4, and a maximum of 99% of MLH-1 is observed at pH 
9.8. The CuISO species is more stable than the NiISO and ZnISO species. The good agreement 
between the theoretical and experimental formation and deprotonation functions, as well as 
low standard deviations and Hamilton R–factors, confirm the validity of this model. 
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Figure 3.11: The distribution curve for the Zn(II) ISO complex (metal to ligand ratio 1:1). 
 
 
3.5.1.5 Discussion 
The equilibrium constants for the complexation of Cu(II), Ni(II) and Zn(II) with ISO are given 
in Tables 3.2-3.4. Log K values of 6.52, 5.11 and 5.71 have been reported in the literature for 
ML species of the Cu(II), Ni(II) and Zn((II) complexes of ISO.30 These values are about 0.19-
1.73 log units larger than the values obtained in our work.  The difference in these values may 
be attributed to the fact that Magare and co-workers30 used a model different from what we 
proposed in our study. A good agreement between the theoretical and experimental formation 
and deprotonation constant as well as a low standard deviation and Hamilton R-factors 
confirms the validity of the model used in the present study. 
The equilibrium constant for the deprotonation of CuISOH is (log βMLH-log βML = (13.77 - 8.98)) 
i.e.  4.79, Table 3.5, which is similar to the pKa of pyridine (5.21).
31 This suggests that it is the 
pyridine that is deprotonated to form ML from MLH. At pH 3.5 CuISOH is the predominant 
species. 
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Table 3.5: Equilibrium constants of the reaction of Cu(II), Ni(II) and Zn(II) with ISO. 
The reaction progress Cu(II) Ni(II) Zn(II) 
MLH ⇌ ML + H+ 4.79 8.00 - 
ML ⇌ MLH-1 + H+
 - 8.96 7.60 
 
The log β value for CuISO is 8.98; this is much higher than the stability constants of 
[Cu(II)(NH3)]
2+ (4.8), [Cu(II)(pyridine)] (2.49), and [Cu(II)(benzyhydrazide)] (1.73), 
suggesting that the ligand is not monodentate.27 The log K values for pyridine complexation 
with Cu(II) and Ni(II) are 2.49 and 1.87 respectively. These are lower than the values obtained 
in this study indicating that the coordination for the CuL and NiL is not via the pyridine 
nitrogen.27 The log β value is quite close to the log β of [Cu(II)(en)]2+ (10.5) suggesting that 
the ligand has a similar binding mode. The formation equilibria for Ni(II) show that this metal 
ion forms relatively stable complexes with ISO, although its stability is lower than that of 
Cu(II).  Trends in the equilibrium constant are in accordance with the Irving-Williams stability 
series.14 The ligand forms a quite stable complex with the metals and could be more selective 
for Cu(II) than Zn(II) and Ni(II).  
 For example, the stability constants (log β values) of the ML species of ISO with Cu(II), Ni(II) 
and Zn(II) are 8.98, 4.92 and 5.50 respectively. The difference in stability of some 3.5-4 log 
units is observed between Cu(II) and the in vivo competitors Ni(II) and Zn(II). The explanation 
for this observation is that the arrangement of the ligand donor atom is such that the metal ion 
is constrained to adopt a square-planar coordination geometry.  As observed in most simple 
systems32 and metalloenzymes,33 Zn(II) prefers a tetrahedral coordination geometry.  
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The proposed structure for this complex is given in Figure 3.12. CuLH is formed by the 
coordination of the isoniazid carbonyl oxygen and hydrazide amino nitrogen atoms, while the 
pyridine group is protonated. The donor atom forms a five-membered chelate ring.    
In the deprotonation of ML to form MLH-1, for Ni(II) and Zn(II), the calculated pKa (log βML - 
log βMLH-1) values were 8.96 and 7.60 respectively.  The value of 8.96 is 0.9 log units lower 
than the first hydrolysis constant of Ni(II) (pKa-OH) of 9.86.
34    Furthermore, the pKa value of 
the formation of MLH-1 species for Zn(II) was 1.57 log units lower than the first hydrolysis 
constant of Zn(II) (pKa-OH) = 9.17.
34 The values of the hydrolysis constant of the metal suggest 
that the deprotonation comes from a coordinated water molecule in the complex.     
 
 
    
                (a)                                    (b) 
Figure 3.12: Possible structures for MLH and ML of the Cu(II) ISO system. 
3.5.2 Ethambutol (EMB) 
3.5.2.1 Protonation 
The ZH-bar function for protonation of EMB is given in Figure 3.13.  The variation of the mean 
number of protons bound to the ligand as a function of pH is given. At pH between 10.48 and 
11.00, ZH-bar is 0, and the ligand is fully deprotonated.   From pH 10.14 to 8.79 ZH-bar rises, 
indicating the protonation of the ligand from L-form to the LH-form in this pH range.  From 
8.54 to 7.51, ZH-bar was constant at approximately ZH-bar = 1.  The graph rises again from pH 
7.5 to 5.8 and then levels up at pH 2, indicating the addition of another proton.  Protonation 
constants of EMB were estimated from the half ZH-bar values, log KLH1 = 9.63, logKLH2 = 6.52, 
and were used as the starting values in ESTA.  
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Figure 3.13: ZH-bar as a function of pH for the protonation of EMB. 
 
The final log β values are given in Table 3.6. The standard deviations were small, and the model 
is accurate since Hamilton R-factors are low, giving confidence in the results.  The theoretical 
and experimental curves are well superimposable, supporting the protonation model. 
Table 3.6: Stability constants (log βpqr) for EMB βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol dm-3 
(NaCl), T = 25 °C. S. dev. denotes standard deviation in log βpqr; 𝑅𝑓
𝐻 is the Hamilton R-factor and 𝑅𝑙𝑖𝑚
𝐻  
its limit, nT is the number of titrations, (nP) is the number of titration points. 
Ligand P q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
 
EMB-H 
 
EMB-H2 
 
 
 
0 
 
0 
 
 
 
1 
 
1 
 
 
 
1 
 
2 
 
 
 
9.63 
 
16.15 
 
 
 
0.005 
 
0.007 
 
 
0.009 
 
 
0.002 
 
 
2(319) 
 
The speciation for EMB protonation titration is given in Figure 3.14. The plots indicate that 
the ligand solution has a mixture of mono- and di-protonated species. The mono-protonated 
species were dominant at higher pH, and the neutral form of the ligand protonates below pH 
6.0. It confirms that LH+ dominates in the pH range 5.3 -10.7. At pH 10.84 there is already 
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more free ligand than LH in solution. Below pH 5.2, the predominant species is [LH2]
 +2 in an 
aqueous solution of this ligand.  
 
 
Figure 3.14: Distribution curve for the protonation of EMB. 
 
EMB shows two pKa values of 9.63 and 6.52 arising from the two amino nitrogen groups. The 
results obtained are higher than literature values, namely log KLH1 of 9.15 and log KLH2 of 
6.10.27 This can probably be attributed to the different experimental conditions for the latter 
determinations, namely T = 30 °C and I = 0.1 mol dm-3. 
3.5.2.2 Copper complexation 
Figure 3.15 shows that the complex formation function (ZM-bar) levels off at a value of ≈1.0 
indicating the presence of CuEMB as a major species. At higher pH, Z-bar rise above 2, 
showing the presence of Cu(EMB)2.  It is dependent on component ratios and concentration, 
suggesting a complex stoichiometry of 1:1 and 1:2. As the titration continues, the curves rise 
steeply and fan back indicating the formation of hydroxo complex species.12  
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Figure 3.15: ZM-bar as a function of pA for the Cu(II) EMB complex. 
 
The total number of dissociable protons on the ligand (n-bar) and the total number of protons 
lost upon complexation of Cu(II) with EMB (Q-bar) are shown in Figure 3.16. At a pH of 2.32, 
QM-bar is zero indicating that complexation has not commenced. The function then increases 
rapidly in the pH range 3.51 to 5.70 to a maximum value of 1.78 indicating that approximately 
two protons are lost due to complex formation. From pH 6.0 to 8.84 QM-bar rises above the n-
bar indicating hydrolysis of the complex.  
 
0
0,5
1
1,5
2
2,5
3
3,5
2 4 6 8 10 12
Z
M
-b
a
r
pA
Theoretical Experimental
56 
 
 
 Figure 3.16: QM-bar as a function of pH for the Cu(II) EMB complex. 
 
The stability constants for the species formed between Cu(II) and EMB from pH 2 to pH 11 
are given in Table 3.7. The theoretical and experimental data are superimposed.  The standard 
deviations and the Hamilton R-factors are low giving confidence to the model. A log β value 
of 10.56 has also been reported for the ML species of the copper complex.35 
Table 3.7: Stability constants (log βpqr) for Cu(II) EMB complex βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 
0.15 mol dm-3 (NaCl), T = 25 °C. S. dev. denotes standard deviation in log βpqr; 𝑅𝑓
𝐻  is the Hamilton R-
factor and 𝑅𝑙𝑖𝑚
𝐻  its limit, nT is the number of titrations, (nP) is the number of titration points. 
Complexes p q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
CuEMB2 
 
CuEMB 
 
CuEMB2H-1 
 
CuEMB2H-2 
1 
 
1 
 
1 
 
1 
2 
 
1 
 
2 
 
2 
0 
 
0 
 
-1 
 
-2 
15.42 
 
10.43 
 
6.65 
 
-3.36 
0.01 
 
0.005 
 
0.01 
 
0.12 
 
 
0.01 
 
 
0.002 
 
 
5(569) 
 
The species distribution curve for the complexes of EMB and Cu(II) are shown in Figure 3.17. 
At pH 2.0, there is 100% of the free metal ion species. ML predominates over a wide pH range 
of 2.90-9.38. ML reaches a maximum of 99% at pH 5.31.  At about pH 6.20, the CuEMB2 
complex starts to form reaching a maximum of 72% at pH 8.17.  The proportion of CuEMB2 
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began to decrease from pH 8.62.  At pH 7.72 the CuEMB2H-1 species starts to form at the 
expense of CuEMB2 reaching a maximum of 64% at pH 9.5. From pH 9.0 formation of 
CuEMB2H-2 commenced and it attained a maximum of 84% at pH 10.73. 
 
Figure 3.17: The distribution curve for the Cu(II) EMB complex (metal to ligand ratio 1:2).  
 
3.5.2.3 Nickel complexation 
ZM-bar for Ni(II)EMB titrations is shown in Figure 3.18. The complexation curves for various 
metal to ligand ratios start at pA = 8.4; the formation function rises and fans back indicating 
the formation of hydroxo or mixed hydroxo complex species in solution. The conformity 
between the theoretical and practical formation curves at the different metal to ligand ratios 
supports the potentiometric model chosen in data analysis. EMB has two dissociable protons, 
and it loses both upon complexation with Ni(II). 
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Figure 3.18: ZM-bar as a function of pA for the Ni(II) EMB complex. 
 
 
 
Figure 3.19 shows that at pH 2.33, the deprotonation function Q-bar is zero and no proton has 
been displaced due to complexation. For pH values above 4.89, Q-bar rapidly rises to intersect 
the protonation curve, n-bar, at a pH of 6.33, reaching a maximum value of 1.62. The falling 
of the curves at about 6.82 shows that complexation is complete.  Above pH 9, the curve rises 
indicating the formation of hydroxo species. It is noteworthy that in the case of the Ni(II) with 
EMB, metal to ligand ratio 1:2 was tried but the ML2 species was always rejected. 
 
Figure 3.19: QM-bar as a function of pH for the Ni(II) EMB complex. 
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The agreement between the theoretical and experimental complex formation curves at different 
metal to ligand ratios supports the potentiometric model chosen in data analysis. The stability 
constants are given in Table 3.8. The calculated formation constants have low standard 
deviation and are comparable with those of Cu(II) complexation. The Hamilton R-factors 
indicate that the model is a good description of the equilibria occurring in solution. 
Table 3.8: Stability constants (log βpqr) for Ni(II) EMB complex βpqr = [MpLqHr]/[M]p[L]q[H]r, I=0.15 
mol dm-3 (NaCl), T = 25 °C. S. dev. denotes standard deviation in log βpqr; 𝑅𝑓
𝐻is the Hamilton R-factor 
and 𝑅𝑙𝑖𝑚
𝐻  its limit, nT is the number of titrations, (nP) is the number of titration points. 
Complexes P q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
 
NiEMB 
 
NiEMBH-1 
 
NiEMBH-2 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
0 
 
-1 
 
-2 
 
7.37 
 
-2.84 
 
-13.42 
 
0.003 
 
0.01 
 
0.01 
 
 
 
0.006 
 
 
 
0.002 
 
 
 
5(233) 
 
The speciation graphs in Figure 3.20 show that ML predominates over a wide pH range of 
5.11-10.13. ML reaches a maximum of 99% at pH 7.87.  At about pH 9.0-10.58, there was the 
formation of MLH-1 and MLH-2, and maxima of 41% were observed. 
 
 Figure 3.20: The distribution curve for the Ni(II) EMB complex (metal to ligand ratio 1:1).  
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3.5.2.4 Zinc complexation 
Figure 3.21 shows the complex formation function (ZM-bar) level off at the value of ≈1.0 for 
mononuclear species formation indicating that ZnEMB is the predominant species. 
  
``  
Figure 3.21: ZM-bar as a function of pA for the Zn(II) EMB complex. 
 
The total number of dissociable protons on the ligand (n-bar) and the total number of protons 
lost upon complexation of Zn(II) with EMB are shown in Figure 3.22. In the pH range 2.3-5.65 
the Q-bar value of zero indicates that no protons have been displaced due to complexation. At 
pH value above 5.8, the deprotonation function Q-bar rapidly rises to intersect the protonation 
curve, n-bar, at a pH of 7.69, with a maximum value of about 1.09. The rising of the curves at 
about pH 8.4 shows that a complex is still forming.  The agreement between the theoretical and 
experimental complex formation curves at the different metal to ligand ratios supports the 
potentiometric model chosen in data analysis. 
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Figure 3.22: QM-bar as a function of pH for the Zn(II)EMB complex. 
 
The stability constants (log βpqr) are given in Table 3.9. The standard deviations are small, and 
the Hamilton R-factor limits are low giving confidence to the chosen model. It is worth noting 
that when Q-bar rises above the n-bar curve, it indicates hydrolysis of the metal ion species, 
forming the species MLH-1. In this instance, different models were tried, but this species was 
always rejected. 
Table 3.9: Stability constants (log βpqr) for Zn(II) EMB complex βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 
mol dm-3 (NaCl), T = 25 °C. S. dev. denotes standard deviation in log βpqr; 𝑅𝑓
𝐻is the Hamilton R-factor 
and 𝑅𝑙𝑖𝑚
𝐻  its limit, nT is the number of titrations, (nP) is the number of titration points. 
 
Complexes P q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
ZnEMB 
 
ZnEMB2 
 
ZnEMBH
  
1 
 
1 
 
1 
1 
 
2 
 
1 
0 
 
0 
 
1 
5.72 
 
9.044 
 
11.86 
0.008 
 
0.03 
 
0.02 
 
 
0.01 
 
 
0.002 
 
 
4(171) 
 
The species distribution curve for the complexation of EMB and Zn is shown in Figure 3.23. 
At pH 2.2, there is 100% of the free metal ion species. Around pH 4.70, the ZnEMBH species 
began to form, reaching a maximum of 28%. The proportion began to fall at pH 6.0, where the 
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formation of ZnEMB commenced and reached a maximum of 84% in the solution; ZnEMB2 
was formed at the expense of ML species. The highest amount of ML2 species present in the 
solution was 39%.   
 
 
Figure 3.23: The distribution curve for the Zn(II) EMB complex (metal to ligand ratio 1:2). 
 
3.5.2.5 Discussion 
The equilibrium constants for the deprotonation of Cu(II), Ni(II) and Zn(II) with EMB are 
given in Table 3.10. The log β value for ML in Cu(II) EMB is 10.43 suggesting that the ligand 
has a similar binding mode as [Cu(II)(en)]2+ (10.5).   
Table 3.10: Equilibrium constants of the reaction of Cu(II), Ni(II) and Zn(II) with EMB 
The reaction progress Cu(II) Ni(II) Zn(II) 
MLH ⇌ ML + H+ - - 6.14 
ML ⇌ MLH-1 + H+ - 10.21 - 
MLH-1 ⇌ MLH-2 +H+ - 10.58 - 
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ML2 ⇌ ML2H-1 + H+ 8.77 - - 
ML2H-1 ⇌ ML2H-2 + H+ 10.01 - - 
 
For ML, the coordination can take place through the two N atoms and two O atoms of the 
ligand. Comparing the log β value of Cu(EMB) (10.43) and that of [Cu(II)(en)]2+ (10.5), it is 
observed that they are close, suggesting that the coordination mode is similar, i.e., through the 
2N of the two amino groups of the ligand.  If the OH is coordinated, it is expected that the log 
β value for Cu(EMB) would be greater than log β for Cu(en).  Two proposed structures are 
shown in Figure 3.24. Based on the above argument the structure (b) is more favourable than 
(a). A similar binding mode has been reported for many Cu-N complexes.36-40  
The log β value of ML2 in solution is 15.42, and it compares well with the log β value for 
[Cu(II)(en)2]
2+ (15.9), indicating similar coordination mode. The ML2 can coordinate through 
the two amino nitrogen atoms from the two ligands. The calculated Cu(II)-assisted 
deprotonation constant associated with the formation of ML2H-1 is the difference between log 
βML2 and log βML2H-1 (8.77, Table 3.10). This could be due to loss of a proton from the 
coordinating water molecule since the pKa is close to the hydrolysis constant of [Cu(OH2)6]
2+.  
In the formation of ML2H-2, there is also a loss of another proton from the coordinating water 
molecule (ML2H-1 ⇌ ML2H-2 + H+) with pKa = 10.01 (Table 3.10).  The proposed structures 
for ML2, ML2H-1 and ML2H-2 are shown in Figure 3.25. The complexes contain five-membered 
rings and are quite stable. A noticeable feature about the complexation of EMB with Cu(II), 
Ni(II) and Zn(II) is the prevalence of the ML species. The difference in the stability observed 
between the metal ions with EMB was 3-4 log units, and the trend agrees with the Irving-
Williams stability order for transition-metal complexes.14 The potentiometric data presented 
could be further supported by ESI-MS measurements in the future. 
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               (a)                                                                           (b)                                                                                                  
 
Figure 3.24: Possible structures for ML of the Cu(II) EMB system.
 
                                                                                                             
                             (a)             (b)                    
 
           
 
 
 
 
 
                                  (c) 
Figure 3.25: Possible structures for ML2, ML2H-1 and ML2H-2 of the Cu(II) EMB system. 
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3.5.3 P-aminosalicylic acid (PAS) 
3.5.3.1 Protonation 
 ZH-bar for protonation of PAS is given in Figure 3.26. The graph rises until it reaches ZH-bar 
=1.28 between pH 5.5 and 2.20, indicating that more than one proton has been added.  
Protonation constants of PAS were estimated from the half ZH-bar values, namely log KLH1 = 
3.78 and log KLH2 = 1.86, which were used as the starting values in ESTA. The experimental 
and theoretical plots are well superimposed. This leads to confidence in the model. 
 
 
Figure 3.26: ZH-bar as a function of pH for the protonation of PAS. 
 
Optimised log  values are given in Table 3.11. These values are lower than those reported in 
the literature (namely log LH1 = 4.08 and log LH2 = 6.08) at a temperature of 25 C and ionic 
strength 0.10 M NaClO4.
27 The standard deviations were small, giving confidence in the results. 
The speciation for PAS protonation titration is given in Figure 3.27. 
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Table 3.11: Stability constants (log βpqr) for PAS βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol dm-3 
(NaCl), T = 25 °C. S. dev denotes standard deviation in log βpqr; 𝑅𝑓
𝐻  is the Hamilton R-factor and 𝑅𝑙𝑖𝑚
𝐻  
its limit, nT is the number of titrations, (nP) is the number of titration points. 
Ligand p q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
 
PAS-H 
 
PAS-H2 
 
0 
 
0 
 
 
 
1 
 
1 
 
 
 
1 
 
2 
 
 
 
3.78 
 
5.64 
 
 
 
0.002 
 
0.005 
 
 
0.007 
 
 
0.001 
 
 
3(419) 
 
 
 
Figure 3.27: Distribution curve for the protonation of PAS. 
 
The LH species predominates at pH between 2.5 and 3.5. Below pH 2.7, the predominant 
species is LH2 in an aqueous solution of the ligand. 
PAS has three protonation sites, but only two are observed for the pH under consideration. PAS 
shows two pKa values of 3.78 and 1.85 arising from the carboxylic acid group and an amino 
group. The pKa of the phenolic hydroxy group of the p-aminosalicylic acid is 13.74 as a result 
of the strong intramolecular hydrogen bond,41-44 and could not be observed because it is higher 
than the pH under consideration. 
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3.5.3.2 Copper complexation  
The formation function for Cu(II) PAS titration is given in Figure 3.28.  Only three species 
were formed in this titration, CuPAS, CuPASH and CuPASH-1. The predominant species is 
CuPAS with log ML = 2.21.   𝑅𝑓
𝐻 and 𝑅𝑙𝑖𝑚
𝐻  are very low, and this gives confidence in the 
proposed model. There is a fanning back of the curve indicating the formation of hydroxo 
(CuPASH-1) species.  
 
 
 
Figure 3.28: ZM-bar as a function of pA for the Cu(II) PAS complex. 
 
Figure 3.29 shows the deprotonation function Q-bar for the Cu(II) PAS complex.  Between pH 
2.44 and 3.27, the Q-bar value is zero indicating that no proton has been displaced due to 
complexation. At pH values above 3.39, the deprotonation function Q-bar rises to intersect the 
protonation curve, n-bar, at a pH of 4.5, reaching a maximum of 0.14. Above pH 4.8, the QM-
bar curve rises indicating the formation of hydroxo species. 
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Figure 3.29: QM-bar as a function of pH for the Cu(II) PAS complex. 
 
Table 3.12 shows the species and the stability constant obtained for the complexation of Cu(II) 
with PAS. The theoretical and experimental formation and deprotonation functions were in 
good agreement; the titration results were also reproducible at various metal: ligand ratios. The 
reported standard deviations of log βpqr values obtained from potentiometry are reasonably low. 
 
Table 3.12: Stability constants (log βpqr) for Cu(II) PAS complex βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 
mol dm-3 (NaCl), T = 25 °C. S. dev. denotes standard deviation in log βpqr; 𝑅𝑓
𝐻  is the Hamilton R-factor 
and 𝑅𝑙𝑖𝑚
𝐻  its limit, nT is the number of titrations, (nP) is the number of titration points. 
Complexes p q r log βpqr S. dev. 𝑅𝑓
𝐻 𝑅𝑙𝑖𝑚
𝐻  nT(np) 
CuPASH 
 
CuPAS 
 
CuPASH-1 
1 
 
1 
 
1 
1 
 
1 
 
1 
1 
 
0 
 
-1 
5.59 
 
2.21 
 
-2.74 
0.02 
 
0.01 
 
0.007 
 
 
0.0
04 
 
 
0.001 
 
 
4(641) 
 
 
The species distribution curve for the complex of PAS and Cu(II) is shown in Figure 3.30. At 
pH 2.1, there is 60% of the free metal ion species. Around pH 2.09-3.15, the CuPASH species 
began to form, rising to a maximum of 40%. The proportion of this species began to fall at pH 
3.3 when the formation of CuPAS commenced with a maximum of 51% in the solution; 
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CuPASH-1 was formed at the expense of the CuPAS species. The highest amount of CuPASH-
1 species present in the solution was 19%. 
 
Figure 3.30: The distribution curve for the Cu(II) PAS complex (metal to ligand ratio 1:1). 
 
 
3.5.3.3 Discussion 
Table 3.13 shows the equilibrium constant for the deprotonation reaction of CuPASH (log βMLH 
- log βML = (5.59 – 2.21), i.e. 3.38. This pKa is closer to that of the amino group in aniline (4.72) 
than the pKa of phenol group in methyl salicylate (9.87)27 suggesting that the amino nitrogen 
is protonated in the formation of MLH.  The proposed structure for CuPASH is depicted in 
Figure 3.31.  
Table 3.13: Equilibrium constants of the reaction of Cu(II) with PAS 
The reaction progress Cu(II) 
MLH ⇌ ML + H+ 3.38 
ML ⇌ MLH-1 + H+ 4.96 
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The complex is formed by the coordination of the metal to the carboxylic and phenolic groups, 
the amino nitrogen group being protonated.  ML is formed by the deprotonation of the amino 
group in MLH, (MLH ⇌ ML+ H+). The MLH-1 species is formed by the deprotonation of ML 
(ML ⇌ MLH-1 + H+) leading to a complex with pKa of 4.96. The deprotonation occurs at a 
much lower pH than the deprotonation of the phenolic OH group of the free ligand, suggesting 
a metal ion induced proton loss.46 The structures of the complexes are shown below for MLH, 
ML and MLH-1 respectively. The complexes all contain six-membered rings, indicating that 
quite stable complexes are formed. 
  
 
                                                           
      
              
         
 
                                
Figure 3.31: Possible structures for MLH, ML and MLH-1 in the Cu(II) PAS system. 
 
Titrations were carried out with Ni(II) and Zn(II) metals, but no complexation could be detected 
under the conditions of our experiment. 
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4.1 UV-Visible spectroscopy 
4.1.1 Introduction 
Transition metals are elements whose atoms have a partially filled d-subshell or which can give 
rise to cations with an incomplete d-subshell.  Colour in transition metal compounds is due to 
charge transfer transition or d-d transition. The d-orbitals of the free transition metal are 
degenerate; the d-orbitals interact with the ligand electron cloud, which results in the d-orbitals 
becoming non-degenerate. When the d-level is not filled, it is possible to promote an electron 
to a higher energy d-orbital by absorption of a photon of light. The visible region of the 
spectrum often possesses the appropriate energy for such transition.  
4.1.2 Theory 
Ultraviolet-visible spectrophotometry (UV-Vis) is an absorption spectroscopy in which a 
molecule absorbs light in the ultraviolet/visible region of the electromagnetic spectrum (200-
400 nm). Absorption of the ultraviolet radiation results in the excitation of the electrons from 
the ground state to a higher energy state. The energy of the ultraviolet radiation that is absorbed 
is equal to the energy difference between the ground state and the higher energy state. This 
technique is usually applied to inorganic ions, molecules and complexes in solution.1 It has 
features for sample identification and is useful for quantitative measurement. It is a frequently 
used technique because of its simplicity, versatility, speed, accuracy and cost-effectiveness.2 A 
spectrum is obtained when the absorbance is plotted against the wavelength. The principle is 
based on the Beer-Lambert law which states that, for a given ideal solution, there is a linear 
relationship between concentration and absorbance provided that the path length is kept 
constant. 
This can be expressed in the following form;  
                                    𝐴 = 𝑙𝑜𝑔10
𝐼𝑂
𝐼
= Ɛ𝐶𝑏                                                                (4.1) 
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where A = Absorbance 
Io = Intensity of light incident upon sample cell 
I = Intensity of the transmitted light 
C = Molar concentration of solute 
b = Length of the sample cell (cm)       
Ɛ = molar absorptivity 
 
If the analyte solution is a combination of different species, the total absorbance, at a specific 
wavelength (Aλ), can be expressed as 
 
                      Aλ = b (Ɛ1λC1 + Ɛ2λC2+ Ɛ3λC3+------- ƐnλCn)    (4.2) 
  
where the superscript λ is the wavelength and subscripts 1, 2, 3…n denote absorbing species.   
Equation, 4.2 can be simplified, as follows: 
 
                                Aλ =   bΣ Ɛ1λC1        (4.3) 
If A, b and C are known, then Ɛ can be calculated.  The wavelength of absorption differs from 
species to species; the maximum wavelength of absorption can be related to the structure of 
the species. λmax values can, therefore, be used to predict structures of complexes.3 One 
important method, Billo’s method, of correlating λmax and ligand field strength is quite well 
understood and thus enables the ligating atoms to be determined.4 
The calculated λmax is expressed as 
 
                                  λmax = 
103
𝑛𝑖𝑣𝑖
       (4.4) 
where ni is the number of equatorial donor groups, and νi is the ligand field of the complex. 
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Many authors5-7 have used UV-Visible spectroscopy to predict the structures of Cu(II) 
complexes. 
4.1.3 Experimental 
Solutions of Cu(II)/EMB, Ni(II)/EMB Cu(II)/ISO, Cu(II)/PAS were prepared in deionised 
water respectively. The pH values of the solutions were adjusted with NaOH/HCl.  The pH 
was determined using a CRISONmicro pH meter equipped with a Ω Metrohm glass electrode. 
The precise amount of NaOH/HCl added was noted. The concentrations of the absorbing 
species were calculated at every pH using the equilibrium constants determined in Chapter 3.  
The absorbances of these solutions were measured with a Hewlett Packard 8452A Diode Array 
spectrophotometer from 200 nm to 800 nm.  A blank was used to correct the absorbance. The 
precise absorbance and the extinction coefficients of individual species could not be measured 
due to the presence of mixed species in solution.   However, it was possible to deconvolute the 
spectra to yield spectra for the individual species. This was done using the program UV-SPEC.8 
The deconvolution was performed one wavelength at a time using the speciation model.  The 
smoothness of the spectra lends confidence to the potentiometric models. The value of λmax 
calculated for the visible spectrometric band was obtained from the deconvoluted spectra. 
4.1.4 Results and Discussion 
4.1.4.1 Cu(II) EMB-System 
Figure 4.1 displays the UV-Visible electronic spectra for Cu(II) EMB at different pH values. 
At low pH, there is little complex formation and the spectrum is that of [Cu(OH2)6]
2+ with 
maximum absorption > 800 nm. The peak changes shape, increases in intensity and shifts to 
higher wavelength with a gradual increase in pH. Also, there is a blue shift from 688 nm in the 
pH range 4.26 to 7.45 and finally shifts further as the pH increases up to 10.61. From the 
potentiometric results, the species formed in this region are ML2, ML2H-1 and ML2H-2. There 
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is the probability of hydrolysis at high pH. Based on the ligand field theory, the gradual shift 
from 688 nm to 646 nm with increasing pH indicates that the donor atoms in the high pH region 
exert higher ligand field strength.  There was no precipitate throughout the entire pH range of 
study.9  
 
 
Figure 4.1: UV-Visible electronic absorption spectra for Cu(II) EMB with [M (0.02M – L (0.01M)] at 
different pH values.   
 
UV-spectra of different species for the Cu-EMB system are revealed in Figure 4.2. The 
comparative evaluation of the potentiometric titration and the UV/Vis data indicate the 
subsequent formation of various complexes as a function of pH and metal to ligand ratio. 
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Figure 4.2: UV-spectra of different species for the Cu EMB2 system. 
 
The smooth graph indicates that the model is appropriate. In an equimolar solution of the 
complexes, CuL was the major species; this has also been predicted for a pH-metric experiment 
taking a 1:1 ratio of Cu(II): EMB.10 The spectra confirm this in Figure 4.2. The ML complex 
has a single peak in the visible region due to the Eg→ T2g transition.  The very close max values 
(Table 4.1) of 684 nm (Ɛ = 82.18 dm3 mol-1 cm-1) for Cu(EMB) and 680 nm for [Cu(II)(en)]2+,11 
suggest that these species have similar coordination mode. It has been reported that mono- and 
bis(ethylenediamine)copper(II) complexes in aqueous solution have distorted octahedral 
structure with two elongated axial bonds.11  
Using Billo’s method, and assuming coordination by 2N and 2O atoms (H2O or OH), a value 
of 663 nm is calculated, i.e. the OH and H2O have the same ligand field parameter.   Hence, 
from the electronic spectral results, it is not possible to decide if the ethanolic groups of EMB 
are coordinated or not.   
 In the case of excess ligand, bis-complexes are present between pH 6-11.  There is a large 
spectral shift in going from CuL to CuL2, indicating that there is a difference in the coordination 
mode.  The λ𝑚𝑎𝑥
𝑑−𝑑   value for CuL2 is 630 nm, which is higher than max of 545 nm for 
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[Cu(II)(en)2(OH2)2]
2+.12  Since the two ligands, en and EMB, differ only in the two ethanolic 
groups, this suggests that the OH is somehow involved in the coordination, perhaps replacing 
the two coordinated water molecules found in [Cu(II)(en)2(OH2)2]
2+. The difference in shift 
observed from ML2 to ML2H-1 and ML2H-2 was not so large, suggesting that the species CuL2H-
1 and CuL2H-2 possess the same coordination mode. These predicted results indicate the same 
structures as proposed by the potentiometric result and are in good agreement with the observed 
max. 
Table 4.1:  UV-Vis spectra Ɛmax (dm3 mol-1 cm-1) and λmax (nm) exp. and calc. values with possible 
donor groups for Cu(II) EMB complexes. 
Species Experimental 
λmax (nm) 
      Ɛmax 
(dm3 mol-1 cm-1) 
Calculated  
λmax (nm) 
Possible donor 
atoms 
CuL 684 82.18 663 2N, 2O 
CuL2 630 155.3 552 4N 
CuL2H-1 624 134.34 552 4N 
CuL2H-2 622 159.10 552 4N 
4.1.4.2 Ni(II) EMB-System 
The absorption spectra as a function of pH for Ni(II) EMB are given in Figure 4.3.  At low pH 
values, the solution is made up of hydrated [Ni(OH2)6]
2+. As the base concentration is 
increased, the intensity of the absorption band at 480 nm increases (curves from pH 9.3 to 
10.61).  
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Figure 4.3:  UV-Visible electronic spectra for Ni(II) EMB at different pH values. 
  
The NiLH-1 and NiLH-2 species presented similar spectroscopic parameters, supporting the 
same coordination in all the Ni(II) ions. At pH 5.29 the solution colour starts to change. Studies 
have shown that for nickel (II) complexes there is often a change of UV-Visible spectra 
representing a regular shift of the complex from octahedral to square-planar structures when 
two or more amino nitrogens coordinate.13,14 
Ni(II) complexes of diamine ligands are known to produce, in solution, an equilibrium mixture 
of complexes.15 In this study, a peak was observed at 610 nm, prominent up to pH 9.3, which 
shifts to 477 nm at pH 10.29. With a further increase in pH, the absorbance remains constant 
but the extinction coefficient increases, as shown in Figure 4.4. Factors such as [OH-], added 
electrolyte and temperature could affect the geometry.16  
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Figure 4.4: UV-spectra of different species for the Ni(II) EMB system.  
 
Nickel(II) amine complexes exhibit characteristic bands for the transition 3A2g 3T1g(F) [588-
572 nm] and 3A2g 3T1g(P) [377-353 nm].17,18 Table 4.2 shows the wavelength and molar 
extinction coefficient values corresponding to maximum absorption of the Ni(II) species 
formed in solution with possible donor groups for this ligand.  
Table 4.2: UV-vis spectra Ɛmax (dm3 mol-1 cm-1) and λmax (nm) exp. and calc. values with possible donor 
groups for Ni(II) EMB complexes.    
Species Experimental  
   λmax (nm) 
      Ɛmax  
(dm3 mol-1 cm-1) 
Possible donor 
atoms 
NiL 604 7 2N, 2O 
NiLH-1 482 53 2N, 2O 
NiLH-2 482 44 2N, 2O 
 
The experimental value (λmax = 604 nm) for NiL is close to the λmax of 617 nm reported for Ni-
N,N-(S,S)-bis[1-carboxy-2-(imidazole-4-yl)ethyl]ethylenediamine (BCIEE) system.19 These 
values strongly support the transition from 3A2g 3T1g(F) for the NiL with an octahedral 
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geometry.  The widely reported electronic spectral studies of nickel(II) amine complexes 
indicate that they are octahedral and paramagnetic.20 As the base concentration is increased, at 
pH 8.53, the solution starts to change colour from light green to yellow.   This corresponds to 
a new band at 482 nm (Figure 4.4) which increases in intensity as the pH is raised.  This band 
is assigned to a 1A1g  1A2g transition, which is expected for absorption by square-planar 
species.21,22 In the pH range 8.53-10.61, NiLH-1 and NiLH-2 predominate. 
 The molar extinction 
coefficient increased from 7 dm3 mol-1 cm-1 for NiL to ~ 50 dm3 mol-1 cm-1 for MLH-1 and 
MLH-2.  Diamagnetic and square-planar geometry has been reported for Ni(II) complexes 
coordinating to amino nitrogen atoms.23-25 This result is in agreement with the potentiometric 
results. 
4.1.5.1 Cu(II) ISO-System 
The UV-visible electronic absorption detected for the Cu-ISO spectrum is shown in Figure 4.5 
below. At low pH 2.33-3.42, the spectrum is the same as that of [(Cu(OH2)6]
2+. As the base 
concentration increased, the absorption bands shifted towards shorter wavelength with an 
increase in intensity for pH values of 3.7 and 4.07. 
 
Figure 4.5: UV-Visible electronic absorption spectra for Cu(II) ISO with [M (0.015 M) – L (0.03 M)] 
at different pH values. 
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The calculated absorption spectra for the individual species are shown in Figure 4.6.  At pH 
3.5, the formation of MLH species has already begun; this is in support of the speciation curves 
in Figure 3.5. 
 
 
Figure 4.6: Calculated spectra of Cu(II) ISO individual species. 
 
The values of λmax and Ɛmax for CuLH are estimated as 746 nm and 42.53 dm3 mol-1 cm-1. The 
λmax for the CuLH is similar to λmax of [Cu(NH3)(OH2)]2+ (745 nm). Similar values have also 
been reported for L-3,4-dihydroxyphenylalanine and δ-DL-hydroxylysine.26,27   This suggests 
that the hydrazide amino nitrogen atoms of ISO are coordinated to the copper, which means 
that the pyridine nitrogen is protonated. This is in agreement with the potentiometric results.  
Unfortunately, the low concentration of ML does not make it possible to calculate the 
spectroscopic data of this species.  
4.1.6.1 Cu(II) PAS-System 
The UV-Visible electronic absorption spectra for a copper complex of p-aminosalicylic acid 
are shown in Figure 4.7. Note that only a limited pH range was studied, as at higher pH 
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precipitate was observed.  According to the potentiometric results MLH, ML and MLH-1 are 
formed within this pH range.   
 
 
Figure 4.7: UV-Visible electronic absorption spectra for Cu(II) PAS with [M (0.01 M) – L (0.02 M)] 
at different pH values. 
 
The deconvoluted spectra for the Cu(II) PAS individual species are revealed in Figure 4.8 
below. At low pH, there is little complex formation and the spectrum is that of [Cu(OH2)6]
2+ 
with maximum absorption > 800 nm. The experimental λmax and molar extinction coefficient 
for ML and MLH-1 are valued as 743 nm, 28.33 dm
3 mol-1 cm-1 and 736 nm, 8.35 dm3 mol-1 
cm-1 respectively. There is a decrease in the λmax of MLH-1 when compared to ML.  This may 
be attributed to deprotonation of the phenolic OH group of the free ligand. For this to occur at 
such a low pH, the metal ion must be involved in a metal ion induced proton loss,28 resulting 
in the spectral change.  These results support the structure proposed from the potentiometric 
results in Figure 3.31.  
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Figure 4.8: Deconvoluted spectra of Cu(II) PAS individual species. 
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4.2 Dermal Absorption Study 
4.2.1 Introduction 
One of the aims of this work was to develop new anti-TB drugs by re-engineering existing 
drugs to improve lipophilicity/hydrophilicity of the ligand and hence bioavailability. This was 
done by synthesising metal complexes of the drugs. The effect of the metal ion on 
bioavailability was assessed by measuring the effect of the metal on the rate of diffusion of the 
ligand through an artificial membrane as a model for skin and comparing this rate with the 
partition coefficient determined in 1-octanol.  
4.2.2. Octanol/Water Partition Coefficients 
Partitioning is the movement of molecules from one phase to another. The partition or 
distribution coefficient (D) is the ratio of the concentration of a compound in two phases of a 
mixture of two immiscible solvents at equilibrium. These coefficients are a measure of 
differential solubility of the compound between two solvents. One of the solvents is water and 
the other one is hydrophobic, such as octanol.  It is useful in estimating the distribution of drugs 
within the body. It indicates the lipophilic-hydrophilic character of the drug molecule. The 
structural activity relationship of a series of drugs can be studied and the change in lipophilicity 
can measure the extent of complexation of a drug. 
Lipophilicity of an organic compound is frequently described with reference to the partition 
coefficient.29-31 Since partition coefficients can range over many orders of magnitude, they are 
usually expressed in logarithmic form. Log P can be defined as the ratio of the concentration 
of the unionised compound at equilibrium, between organic and aqueous phases.   
                                   log 𝑃 = log 
[𝑢𝑛𝑖𝑜𝑛𝑖𝑧𝑒𝑑 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑]𝑜𝑟𝑔
[𝑢𝑛𝑖𝑜𝑛𝑖𝑧𝑒𝑑 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑]𝑎𝑞
                                              (4.5) 
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The octanol: water system has been widely used as a model of the lipid phases as it mimics the 
lipid membrane/water systems found in the body.32 Partition coefficients can be measured 
using the following methods: shake flask method, slow stirring method, electrochemical 
method.  The most common method of determining partition coefficients is the shake flask 
method because it is accurate for both neutral and charged compounds, and knowing the 
chemical structure of the compound beforehand is not important.33-35 Factors such as 
temperature, pH, mutual phase saturation concentration, as well as the nature of the solvent 
used and solute examined affect the measured value of the partition coefficient.36 
Some drugs may be poorly absorbed after oral administration even though they are available 
predominantly in the unionised form in the gastrointestinal tract. This is attributed to the low 
lipid solubility of the unionised molecule. This parameter, therefore, influences the transport 
and absorption processes of drugs, and it is one of the most widely used properties in 
quantitative structure-activity relationships.  In the human body, the drug must traverse several 
body tissues before they can impart their therapeutic effect. Transport across the skin and bio-
membrane, in general, is a process of limited diffusion governed by the drug’s chemical and 
physical properties such as lipophilicity.37 The degree of ionisation is determined by the pKa 
of a drug for the unionised drug. If a drug is lipid soluble, it will be well absorbed into the 
systemic circulation, and if poorly lipid soluble, it will be poorly absorbed. For optimum 
absorption, the drug should be soluble in the fluid at the absorption site and highly lipid soluble 
to facilitate the partitioning of the drug in the lipoidal membrane and into the systemic 
circulation. It is noteworthy that there should be a balance in the hydrophilicity and lipophilicity 
of drugs for optimum bioavailability. A positive log Poct/aq (log 1 to 3), indicates the ability to 
diffuse across the membrane. Log Poct/aq greater than 5 suggests that the drug is insoluble and 
can aggregate in the absence of fluid.38 
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4.2.3 Experimental 
The partition coefficients of the pure drugs as well as those of their metal complexes were 
determined using the shake flask method. The organic phase was saturated with water.39 A 
0.0001 M solution of the drug was prepared in deionised water. 5 ml of the solution was 
dispersed into ten glass vials, and the pH of the solution was adjusted using 0.100 mol dm-3 
NaOH.40,41 5 ml of 1-octanol (99%) was added to each solution. The mixture was shaken for 
five minutes and allowed to stand at a constant temperature of 25  0.1 C.  Two ml of each 
phase was pipetted into a vial, and the concentrations of the drug were determined 
spectrophotometrically. Triplicate readings were taken, and the average was calculated. For 
measurement of the partition coefficients of the metal complexes, an analogous procedure was 
used with solutions containing metal and drug in a 1:1 molar ratio.    
4.2.4 Results and Discussion 
4.2.4.1 Isoniazid 
Figure 4.9 shows the speciation graph, and the partition coefficients log Poct/aq of ISO as a 
function of pH. A notable feature about Figure 4.9 is that all the log Poct/aq values were negative. 
Negative values of log Poct/aq suggest that ISO is hydrophilic.
42  
 
Figure 4.9: Log Poct/aq and speciation graph as a function of pH for ISO system. 
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From Figure 4.9 the speciation graph shows that from pH 3.77-9.36 the predominant species 
in solution is LH; the value of log Poct/aq at this pH is -0.61 and can be assigned to the presence 
of LH species. The log Poct/aq value of -0.67 has been reported in literature for isoniazid.
43 
4.2.4.2 Cu-Isoniazid Complex 
The distribution coefficient curve and the speciation graph for the Cu-ISO system plotted as a 
function of pH is shown in Figure 4.10. It is evident that complexes of Cu(II) ISO are more 
soluble in water than in 1-octanol since the log Poct/aq values were negative.  
 
 
Figure 4.10: Log Poct/aq and speciation graph as a function of pH for 1:1 Cu-ISO system. 
 
At pH 2.2 complexation has commenced. The distribution coefficient did not change 
significantly between pH 2.5 and 4.8. The speciation graph for Cu(II) ISO mirrors the 
formation of the two complexes, MLH and ML. Log Poct/aq increases from -1.40 at pH 2.2 to 
stabilise at -0.60 after pH 3.7 when the ISO is fully complexed.  The results suggest that both 
species, MLH and ML, have the same partition coefficient of -0.60. 
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4.2.4.3 Ni-Isoniazid Complex 
The negative values of log Poct/aq for Ni(II) ISO show that this complex is hydrophilic (Figure 
4.11). The partition coefficient is rationalised with reference to the speciation diagram. 
 
 
Figure 4.11: Log Poct/aq and speciation graph as a function of pH for 1:1 Ni(II) ISO system. 
 
Complexation commenced at pH 2.2. In the pH range 4.4-7.99, the predominant species is 
MLH. Therefore the log Poct/aq values of -0.75 can be attributed to the presence of MLH species. 
The partition coefficient did not change very significantly with pH (from 7.99-9.61). The 
speciation curves showed that mixed species were observed at the same pH values. Therefore 
the log Poct/aq values were not for a single species. The log Poct/aq value of -0.68 can be attributed 
to the ML and MLH-1 present at these pH values on the speciation graph.  
4.2.4.4 Zn-Isoniazid Complex 
The log Poct/aq and the speciation graph as a function of pH are shown in Figure 4.12. The 
negative values of log Poct/aq for Zn(II) ISO show that this complex is hydrophilic. 
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Figure 4.12: Log Poct/aq and speciation graph as a function of pH for the 1:1 Zn(II) ISO system. 
 
The speciation graph shows the existence of three ligand species in the pH range 2.2 to 10.2. 
Log Poct/aq of -0.85 can be ascribed to the ML and MLH-1 species present between pH 7.4 and 
9.8. 
 
4.2.4.5 Rifampicin and its Metal Complexes 
The partition coefficients log Poct/aq as a function of pH for rifampicin (RFN) and its complexes 
are shown in Figure 4.13. The partition coefficient could not be rationalised by reference to a 
speciation graph because the pKa of rifampicin is lower than the pH of our present 
potentiometric study. The log Poct/aq values for the ligand and the complexes are all positive 
indicating that the drug is lipophilic and is likely to diffuse into lipid bilayers. The log Poct/aq of 
RFN increased from pH 2.4 to 3.36 after which it levelled off at a log P value of 2.3 throughout 
the entire pH range; it is close to the reported value of 2.4 reported for RFN. 44  
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Figure 4.13: log Poct/aq of RFN and its metal complexes as a function of pH. 
 
The incorporation of metals into the system has reduced the value of log Poct/aq; this can imply 
increasing the rate of diffusion of the ligand through the membrane. The reduction of log Poct/aq 
by the metals suggests that the drug will be more water-soluble and will not aggregate in the 
absence of fluid. 
 4.2.4.6 Pyrazinecarboxamide and its Metal Complexes 
The partition coefficients log Poct/aq of PZA complexes as a function of pH is shown in Figure 
4.14 below. The partition coefficient could not be explained in terms of speciation distribution 
because the pKa of PZA could not be detected under the conditions of our potentiometry 
experiment. The log Poct/aq values for the complexes were rationalised with respect to log P of 
PZA. The log Poct/aq for PZA is in close agreement with the value of -0.60, reported in the 
literature.46 For PZA-Cu the value of log P increased from -0.82 (pH 3.62) to -0.52 (pH 5.85) 
after which a constant log P value of -0.50 was observed from pH 6.62.  For PZA-Ni the log 
Poct/aq increased steadily with the increase in pH.  For PZA-Zn the log Poct/aq value of -0.51 was 
observed throughout the pH range. Log Poct/aq for PZA-Zn is thus independent of pH. 
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Figure 4.14: log Poct/aq of PZA and its metal complexes as a function of pH. 
 
It was observed that the incorporation of metals does not have a significant effect on the 
partition coefficient of PZA. 
4.2.4.7 P-aminosalicylic acid 
Partition coefficients log Poct/aq of PAS and speciation curves as a function of pH are shown in 
Figure 4.15. The log P values are all positive, indicating that the ligand is lipophilic. 
 
  
Figure 4.15: Log Poct/aq and speciation graph as a function of pH for the PAS system. 
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The speciation diagram for PAS shows the presence of LH and LH2 species between pH 2.0 
and 4.0. The log Poct/aq value of 1.58 can be assigned to the LH and LH2 species. As the pH 
increases, the value of Poct/aq is reduced to about 0.80 and was steady throughout the entire pH 
range. The speciation graph reveals the presence of PAS between pH 4.0 and 11.0, and 
therefore log Poct/aq of 0.87 can be attributed to the presence of  PAS. A log Poct/aq value of 0.91 
has been reported in the literature for PAS.47  
4.2.4.8 P-aminosalicylic acid-Cu(II) complex 
The distribution curve and the speciation graph for Cu(II) PAS as a function of pH are given 
in Figure 4.16. The distribution curve shows that log P decreased with an increase in pH (from 
pH 2.86 to 3.70) after which it became constant. 
 
 
Figure 4.16: Log Poct/aq and speciation graph as a function of pH for the 1:1 Cu(II) PAS system. 
 
From the speciation curve, around pH 2.09 -3.15, MLH is the predominant species; the log 
Poct/aq value of 0.075 at this pH range can be assigned to MLH species. The speciation curve 
reveals the presence of ML and MLH-1 species from pH 3.13 to pH 4.46; the distribution 
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coefficient did not change significantly in this pH range. Therefore the log Poct/aq were not for 
a single species. The log Poct/aq value of 0.066 can be attributed to the ML and MLH-1 species 
present at these pH values on the speciation graph.  
 
4.2.4.9 P-aminosalicylic acid and its Ni(II) and Zn(II) complexes 
The octanol/water partition coefficients as a function of pH for PAS and its Ni(II) and Zn(II) 
complexes are given in Figure 4.17. The shapes of the distribution curves were not due to metal 
complexation as, from potentiometric results, no complexation could be detected under the 
conditions of our experiment. Instead, the partition coefficient reflects the speciation of the 
ligand on its own.  
 
 
Figure 4.17: log Poct/aq of PAS complexes as a function of pH. 
Although no metal complexation takes place, the presence of the metal has had a small effect 
on the partition coefficient, decreasing it by ~0.4 log units.  The reason for this behaviour is 
not known. 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
2 3 4 5 6 7 8 9 10
lo
g
 P
o
ct
/a
q
pH
PAS PAS-Ni PAS-Zn
97 
 
The ligand is more lipophilic at acidic pH for both the ligand as well as when the metal was 
incorporated. The pKa of the carboxylic group is 3.78, which explains the decrease in log Poct/aq.  
A partition coefficient of 1.6 could therefore be assigned to the PAS when the carboxylic group 
is protonated (i.e. neutral) and this drops to 0.8 when the carboxylic group ionises. 
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4.2.5 Conclusion 
The distribution graph for ISO and its complexes was rationalised in terms of the speciation 
graph; it was observed that the log Poct/aq values were all negative, suggesting that they are 
hydrophilic. The partition coefficient data are consistent with the species revealed by the 
speciation graph. 
A positive log Poct/aq value obtained for RFN and its metal complexes implies they are 
lipophilic. The pKa of RFN which is lower than the pH of our present potentiometric study 
made the rationalisation by reference to speciation graph impossible. However, the presence of 
metals reduced the log Poct/aq value of RFN from 2.30 to ~ 1.05 log units.  
The values of log Poct/aq are all negative for PZA and its complexes. The presence of metals 
does not have much effect on the partition coefficient.  
PAS, as well as its metal complexes, are lipophilic since the log P values are positive. The 
results of log Poct/aq values for PAS with copper agrees well with the speciation graph obtained 
from the potentiometric study. Metal complexation was not detected for nickel and zinc under 
our potentiometric conditions, but their presence decreased the log Poct/aq value of PAS by ~0.4 
log units. 
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4.4 Franz Diffusion Cells 
4.4.1 Introduction 
The skin is the largest organ in the body; it creates a boundary between the body and the outer 
environment and is metabolically active.48,49 Solute can penetrate through the skin via a 
transepidermal and a transappendageal route. The amount of drug that diffuses through the skin 
is determined by factors such as the physicochemical properties of the drug and the medium, 
in addition to the dosing conditions.  
Permeability through biological membranes is significant in the absorption and distribution of 
medications. Poor permeability can arise due to several structural features, as well as 
membrane-based efflux mechanisms. Poor permeability can result in poor absorption across 
the gastrointestinal mucosa or poor distribution throughout the body. Dermal absorption of 
water has been tested in various species, including red cell membranes of dog, cat and beef.50 
The permeability coefficient (Kp) is the velocity of drug passing through the membrane in cm 
h-1. The equation below gives the relation between permeability coefficient and steady-state 
flux: 
                                     𝐾𝑝= 
𝐽
𝐶𝑖
                                                                    (4.6) 
where, J is the amount of permeant crossing the membrane at a constant rate (mg cm-2 h-1), and 
Ci is the concentration of a ligand in the donor phase. The amount of permeant crossing the 
membrane J can be expressed as: 
                                  𝐽 =
𝑄
𝐴.𝑡
                                                                     (4.7) 
The steady-state flux J dictates the rate and ease with which the permeant crosses a membrane 
under specified conditions. It is a dynamic property expressed in the unit of area per time (h).46 
The temperature is kept constant, and the magnitude of the diffusion coefficient is dependent 
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on the properties of the drugs and the diffusion medium as well as the interaction between 
them. The diffusion coefficient is an important parameter indicative of the diffusion mobility. 
It is prescribed for a given pair of species. The higher the diffusivity (of one substance with 
respect to another), the faster they diffuse into each other. 
 Q (mg) is the quantity of ligand/complex transported through the membrane in time t (h), and 
A is the area of exposed membrane in cm2. The amount of permeant crossing the membrane is 
calculated from the slope of the graph.42 The Franz diffusion cell method is one of the most 
common systems employed in in vitro skin diffusion studies, and it provides insight into the 
relationship between skin, drug and formulation51,52, and primarily it is developed to determine 
the absorption and the rate of penetration of transdermal medication.53 The Franz cell is used 
with excised human or animal skin. Artificial membranes are also employed when the 
biological membrane is not readily available. For a biological membrane, factors such as the 
time obtained, conditions of preservation and treatment, age, sex and weight of the membrane 
must be taken into consideration during the studies. These factors do not apply when an 
artificial membrane is used. The artificial membrane should possess minimum diffusion 
resistance to drugs and act as a barrier between the donor and acceptor phases.54-56 Artificial 
membrane has shown to be a promising model for biological membrane; it increases 
permeation rate and drastically reduces transport time from over 10 to 2 h.57-59 By eliminating 
the complexity of human and animal skin, the simple homogenous material is particularly 
useful for studying the basic mechanisms controlling passive  transport.60-62  
Ottaviani et al.63 investigated the permeability coefficient of some drugs through human skin 
and an artificial membrane comprising a dimethylsiloxane (silicone) membrane. Silicone 
membranes have been extensively used as simple lipid-like membrane models for in vitro 
percutaneous penetration studies,64-66 because they offer a nonporous, hydrophobic, and 
relatively inert, reproducible barrier.67 The permeability coefficients obtained through human 
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skin (log Kp) and through a silicone membrane using a diffusion cell (log Kp(sil)) are listed in 
Table 4.3 below. 
Table 4.3: Permeability coefficients obtained through human skin (log Kp) and silicone membrane using 
diffusion cell (log Kp(sil)) 
Compound log Kp
68 log Kp(sil)
64 
Nicotine -5.26 -4.29 
Phenol -5.64 -4.45 
4-nitrophenol -5.81 -5.08 
Lidocaine -5.3269 -4.05 
Salicylic acid -5.45 -4.70 
Thymol -4.83 -3.68 
 
The results showed that the artificial membrane could mimic the main properties of human 
stratum corneum.  
The Franz cell is based on vertical diffusion between donor and acceptor phases. In the present 
study, a horizontal Franz cell (Figure 4.18) fitted with an artificial membrane (Cerasome 9005), 
was used.  Cerasome 9005 was purchased from Germany (Lipoid GmbH, Ludwigshafen, 
2008). This membrane is a lipid solution which imitates human stratum corneum, which is the 
outer layer of the epidermis; it forms a barrier to protect underlying tissues from infection, 
dehydration, chemical and mechanical stress. The lipids of the human stratum corneum 
regulate skin permeability. The most suitable method of imitating partition into a biological 
membrane is using a membrane composed of numerous phospholipids as a model system.70 
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Figure 4.18:  A modified Franz diffusion cell apparatus. 
 
1.  Donor phase filled with 20 ml ligand/complex. 
2.  Receiver phase filled with 0.02 M HCl. 
3. The artificial membrane (0.065 g). 
4. Passive diffusion direction. 
5. Clamp. 
6. Stirrer bar. 
7. Magnetic stirrer. 
8. Burette stand for the clamp. 
Drug 
5 
1 2 
6 
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4.4.2 Experimental 
The receiver cell was filled with 20 ml of 0.02 M HCl. The ligand/complex solutions (0.002 
M) were prepared in 0.02 M HCl, and a 20 ml sample at pH 2.0 was placed in the donor phase 
compartment along with semi-permeable membrane used as a barrier between donor and 
receptor compartments. The experiment was carried out at pH 2.0 to mimic the acid condition 
of the stomach. The artificial membrane was prepared using a filter paper (Whatman, 2.54 cm2 
disc and thickness 0.002 cm) which was submerged in Cerasome 9005, dried for a few minutes 
at room temperature. To determine the quantity of lipid absorbed, the membrane was weighed 
before and after soaking in Cerasome 9005. The available diffusion area between the cells was 
0.6217 cm2. The medium was magnetically stirred for uniform drug distribution and was 
maintained at a temperature of 25 °C; samples were removed at different times. During the 
experiment, both cells were covered to prevent evaporation. The concentration of the ligand in 
the complexes was determined spectrophotometrically. The wavelength of maximum 
absorption was determined for the ligands ISO, RFN, PAS and PZA as 263 nm, 479 nm, 265 
nm and 269 nm respectively. Measurements were done in triplicate, using the points from 0-
56 hours. Results are expressed as mean ± SE. 
4.4.3 Results and Discussion 
4.4.3.1 Isoniazid and its Metal Complexes 
Plots of the variation of ISO concentration with time at pH 2 are shown in Figure 4.19. Table 
4.4 shows the diffusion flux, J, permeability coefficient Kp and shown graphically in Figures 
4.20 and 4.21, respectively. 
The steady-state flux was calculated from the gradient in Figure 4.19, and the permeability 
coefficient (Kp) obtained from the relationship between the flux, and the initial concentration 
of ISO added to the donor phase. 
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Figure 4.19: Variation in the amount of ISO vs time through a Cerasome 9005 membrane at pH 2.00. 
 
ISO has a molecular weight of 137.14 g mol-1, which is less than 600 g mol-1 and so is ideally 
suited for passive diffusion across the skin and biomembranes.71 
Table 4.4: Flux of diffusion J (mg cm-2 h-1) and permeability coefficient Kp (cm h-1) of ISO and its metal 
complexes through Cerasome 9005 membranes at pH 2.00. 
Drug and Metal Complexes J (mg cm-2 h-1) x 10-3  Kp (cm h-1)   
ISO 8.6 ± 1.1 0.068 ± 0.009 
ISO-Cu 20.6 ± 2.3 0.400 ± 0.045 
ISO-Ni 7.2 ± 1.2 0.200 ± 0.031 
ISO-Zn 15.8 ± 1.1 0.145 ± 0.011 
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Figure 4.20: Influence of metals on the flux of ISO through Cerasome 9005 membrane in modified 
Franz cell from 0-56 hrs at pH 2.00. 
 
 
From Figure 4.20, above, the steady-state flux, which is the total amount of ISO that permeates 
the membrane per unit area per unit time, is in the order Cu(II) > Zn(II) > ISO > Ni(II). Note 
that this flux is dependent on the initial concentration in the donor phase, which was not the 
same in each experiment.  The presence of Cu(II) and Zn(II) has increased the rate at which 
ISO passes through the membrane.  
  
 
Figure 4.21: Effect of metals on the permeability of ISO through Cerasome 9005 membrane at pH 
2.00. 
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Included in Figures 4.19 and 4.21 are the results for ISO without coordinating metal. From 
Figure 4.21, it is clear that the metals can promote the passage of the ligand through the 
membrane. The permeability is in the order Cu(II) > Ni(II) > Zn(II). ISO possesses three 
ionisation constants (pKa), 1.8 (hydrazine nitrogen); 3.5 (pyridine nitrogen) and 10.8 (acidic 
group) with an overall isoelectric point (pI) of 1.82.  Since the pH of the vehicle is higher than 
that of the pI, the ISO molecule will, therefore, carry a net negative charge.72 The permeability 
of ISO has been reported as 0.033  0.006 cm h-1 where porcine skin was used.73 In our 
experiment, the permeability coefficient was 0.068  0.009 cm h-1 which is higher than reported 
but is expected for an artificial membrane.74   
  
4.4.3.2 Rifampicin and its Metal Complexes 
The variation of the concentration of RFN with time through Cerasome 9005 membrane at pH 
2.00 is revealed in Figure 4.22.  
 
Figure 4.22: Variation in the amount of RFN vs time through Cerasome 9005 membrane at pH 2.00. 
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The value of the steady flux J (mg cm-2 h-1) and the permeability coefficient Kp (cm h
-1) are 
shown graphically on Figures 4.23 and 4.24 respectively. The corresponding standard 
deviations for RFN and its complexes are shown in Table 4.5.  
 The flux of RFN is independent of time and this is reflected in the standard error. 
Table 4. 5: Flux of diffusion J (mg cm-2 h-1) and permeability coefficient Kp (cm h-1) of RFN and its 
metal complexes through Cerasome 9005 membrane at pH 2.00. 
Drug and Metal Complexes J (mg cm-2 h-1) x 10-3 Kp (cm h-1) 
RFN 0.34 ± 0.3 0.003 ± 0.002 
RFN-Cu 2.5 ± 2.5   0.07 ± 0.06 
RFN-Zn 0.21 ± 0.5 0.002 ± 0.003 
 
 
Figure 4.23: Influence of metals on the flux of RFN through Cerasome 9005 membrane in modified 
Franz cell from 0-56 hrs at pH 2.00. 
 
 
From Figure 4.23 and 4.24, it was observed that the incorporation of copper improved the 
amount of RFN crossing the membrane significantly. Zn(II) did not enhance the amount of 
ligand diffusing through the membrane. This finding may have implications for the study of 
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the mechanism of action of RFN and possible copper supplement for improving the activity of 
RFN.       
 
Figure 4.24: Effect of metals on the permeability of RFN through Cerasome 9005 membrane at pH 
2.00. 
 
The permeability coefficient of RFN has previously been determined in three segments of the 
rat intestine by employing the everted gut sac model; the apparent permeability coefficient 
values were 4.856×10-6, 2.11×10-6 and 2.149×10-6 cm sec-1 in the duodenum, jejunum and 
ileum respectively.75 A permeability coefficient of 0.0034 ± 0.0020 cm h-1 (9.4×10-7 cm s-1) 
was obtained when an artificial membrane was used in the present study. The incorporation of 
copper enhanced the permeability of RFN 20-fold.  
4.4.3.3 P-aminosalicylic acid and its Metal Complexes 
A plot of the amount of PAS, against time, passing through the Cerasome 9005 membrane at 
pH 2.00 is depicted in Figure 4.25.  
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Figure 4.25: Variation in the amount of PAS vs time through Cerasome 9005 membrane at pH 2.00. 
 
Flux values J (mg cm-2 h-1), permeability coefficient Kp (cm h
-1) and their corresponding 
standard errors (SEs) for the metal complexes of PAS are shown in Table 4.6. The flux value 
J and permeability coefficient Kp are presented graphically in Figures 4.26 and 4.27, 
respectively.  
Table 4.6: Flux of diffusion J (mg cm- 2 h-1) and permeability coefficient Kp (cm h-1) of PAS and its 
metal complexes through Cerasome 9005 membrane at pH 2.00. 
Drug and Metal Complexes J (mg cm-2 h-1) x 10-3 Kp (cm h-1)   
PAS 0.8 ± 0.2 0.14 ± 0.03 
PAS-Cu 1.0 ± 0.2 0.15 ± 0.03 
PAS-Ni 1.1 ± 0.3 0.13 ± 0.04 
PAS-Zn 1.9 ± 0.3 0.27 ± 0.04 
 
The incorporation of Zn(II) increased the diffusion of the ligand through the membrane, while 
Cu(II) and Ni(II) did not improve diffusion (Figure 4.26). The effect of incorporation of metals 
on permeability of the ligand is shown in Figure 4.27. In the light of this result, if Zn(II) is 
incorporated into PAS then an increase in drug absorption could be expected. 
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Figure 4.26: Influence of metals on the flux of PAS through Cerasome 9005 membrane in modified 
Franz cell from 0-56 hrs at pH 2.00. 
 
 
 
 
 
Figure 4.27: Effect of metals on the permeability of PAS through Cerasome 9005 membrane at pH 
2.00. 
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4.4.3.4 Pyrazinecarboxamide and its Metal Complexes 
The effect of metals on the diffusion of PZA through Cerasome 9005 membrane at pH 2.00 
was studied for 54 h. The results are presented in Figure 4.28.  
 
 
Figure 4.28: Variation in the amount of PZA vs time through Cerasome 9005 membrane at pH 2.00. 
 
The flux value and permeability coefficients are presented in Table 4.7 and are shown 
graphically in Figures 4.29 and 4.30 respectively. 
Table 4.7: Flux of diffusion J and permeability coefficient Kp of PZA complexes through Cerasome 
9005 membrane at pH 2. 
Drug and Metal Complexes J (mg cm-2 h-1) x 10-3 Kp (cm h-1)   
PZA 2.0 ± 0.1 0.100 ± 0.006 
PZA-Cu 1.70 ± 0.09 0.098 ± 0.005 
PZA-Ni 0.2 ± 0.1 0.103 ± 0.009 
PZA-Zn 1.10 ± 0.04 0.089 ± 0.004 
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Figure 4.29: Influence of metals on the flux of PZA through Cerasome 9005 membrane in modified 
Franz cell from 0-56 hrs at pH 2.00. 
 
 
 
Figure 4.30: Effect of metals on the permeability of PZA through Cerasome 9005 membrane at pH 
2.00. 
 
It was observed that the presence of Cu(II), Ni(II) and Zn(II) did not significantly have an 
impact on the diffusion and permeability coefficient of PZA through the membrane. 
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4.4.3.5 Comparison of permeability coefficients Kp for the ligands and complexes. 
The plot of the permeability coefficients Kp for the ligands (ISO, RFN, PAS and PZA) and their 
complexes are shown in Figure 4.31. 
 
 
Figure 4.31: Comparison of the permeability coefficients for the ligands and complexes. 
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present study shows that the permeability coefficients of the ligands are in the order PAS > 
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-1, while Zn(II) enhanced the permeability coefficient of PAS with a Kp 
value of 0.265 cm h-1. The incorporation of Cu(II), Ni(II) and Zn(II) had no effect on PZA. The 
values of Kp were then compared with that of metoprolol which was chosen as the reference 
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in the present study are all lower than the Kp of the reference compound (metoprolol). Therefore 
the drugs, as well as their complexes, can be classified as low-permeability drugs. 
 
4.4. Relationship between logarithm of permeability coefficient log Kp and octanol/water 
partition coefficient log Poct/aq of the ligand and complexes. 
Previous studies by Potts and Guy78 have analysed permeability data using a model which 
depends upon the size of the drug (MW), and its octanol/water partition coefficient. A 
correlation between log Kp and log Poct/aq was therefore investigated since the two parameters 
have been determined. Tables 4.8-4.11 show the permeability and partition coefficient values 
of the ligands in the presence of the different metals. Graphical representations of these data 
appear in Figures 4.32-4.35.   
Table 4.8: The permeability and partition coefficient values of ISO in the presence of the different 
metals. 
Drug and Metal Complexes -log Poct/aq -log Kp   
ISO 0.61  0.02 1.167  0.016 
ISO-Cu 0.61  0.03 0.398  0.002 
ISO-Ni 0.71  0.03 0.699  0.004 
ISO-Zn 0.78  0.02 0.839  0.006 
  
 
Figure 4.32: Logarithm of permeability coefficient log Kp plotted against logarithm of partition 
coefficient for ISO. 
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Table 4.9: The permeability and partition coefficient values of RFN in the presence of the different 
metals. 
Drug and Metal Complexes -log Poct/aq -log Kp   
RFN 2.310  0.008 2.47  0.22 
RFN-Cu 0.750  0.018 1.16  0.04 
RFN-Ni 1.640  0.014 - 
RFN-Zn 1.750  0.007 2.98  0.74 
 
 
Figure 4.33. Logarithm of permeability coefficient log Kp plotted against logarithm of partition 
coefficient for RFN. 
 
Table 4.10: The permeability and partition coefficient values of  PAS in the presence of the different 
metals. 
Drug and Metal Complexes log Poct/aq -log Kp   
PAS 0.800  0.030 0.867  0.001 
PAS-Cu 0.060  0.001 0.827  0.001 
PAS-Ni 0.510  0.006 0.883 + 0.002 
PAS-Zn 0.510  0.018 0.577  0.001 
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Figure 4.34: Logarithm of permeability coefficient log Kp plotted against logarithm of partition 
coefficient for PAS. 
 
Table 4.11: The permeability and partition coefficient values of PZA in the presence of the different 
metals. 
Drug and Metal Complexes -log Poct/aq -log Kp   
PZA 0.560  0.018 1.0000  0.001 
PZA-Cu 0.510  0.017 1.0087 0.001 
PZA-Ni 0.420  0.002 0.9871  0.001 
PZA-Zn 0.510  0.002 1.0451  0.001 
 
 
 
Figure 4.35: Logarithm of permeability coefficient log Kp plotted against logarithm of partition 
coefficient for PZA. 
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Figures 4.32-4.35 show the possible correlation between the logarithm of permeability 
coefficient log Kp and the octanol/water partition coefficient log Poct/aq of the ligands alone as 
well as in the presence of metal ions. The correlation coefficients obtained from Figures 4.32, 
4.34 and 4.35 are 0.0015, 0.0014, and 0.1130 for ISO, PAS and PZA respectively. The values 
are far from 1 demonstrating that there is no correlation between the logarithm of permeability 
and the logarithm of octanol/water partition coefficient of the ligands. The correlation 
coefficient obtained for RFN, in Figure 4.33, is 0.6449 which indicates that 65% of log Kp 
could be explained by log Poct/aq.  However, the very low diffusion and associated errors 
encountered with RFN make this suspect.   
Since Potts and Guy78 did not distinguish between ligands, we therefore decided to plot the 
log Kp vs log Poct/aq as well as the log Kp vs molecular weight (MW) data obtained for all 
ligands and their complexes together (Figures 4.36 and 4.37). 
 Figure 4.36: Logarithm of permeability coefficients log Kp plotted against logarithm of partition 
coefficient for all ligands and complexes. 
 
 
The correlation coefficient obtained from Figure 4.36, R2 = 0.72, indicates that there is a 
correlation between permeability and partition coefficient. 
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 Figure 4.37: Logarithm of permeability coefficients log Kp plotted against molecular weight for all 
ligand and complexes. 
 
Linear regression analysis of log Kp vs MW (Figure 4.37) gave an R
2 value of 0.59.  The results 
of the correlation from Figures 4.36 and 4.37 show that there is a correlation between log Kp 
and either log Poct/aq or MW.  
Potts and Guy78 have proposed a quantitative structure-permeability relationship model which 
depends upon both the size of the drug (MW) and Poct/aq.
78     
Log Kp = Log (D
0/h) + f Log Ko/w – βMW                                                             (4.8) 
where, D0 is the diffusivity of a hypothetical molecule having zero molecular weight, h is the 
membrane thickness, f is a constant which accounts for the difference between the partitioning 
domain presented by octanol and the membrane lipids, and β is a constant which includes a 
conversion factor for the substitution of molecular weight for molecular volume. 
The average value of the intercept log (D0/h), the slope (β) and f after considering species Cu(II), 
Ni(II) and Zn(II) complexes of ISO, PAS and PZA, as well as Cu(II) and Zn(II) complexes of 
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RFN, each solvated with 2H2O molecules, were as follows: log (D
0/h) = 0.26  0.16, β’ = 0.00078 
 0.0001 and f = 0.76  0.24. Equation 4.8 can thus be written as     
Log Kp = 0.26 + 0.76 Log Poct/aq – 0.00078 MW                                      (4.9)                  
Multiple linear regression analysis of log Kp upon log Poct/aq and MW gave an R
2 value of 0.77, 
which means that there is a correlation between log Kp and log Poct/aq or MW.  The values of 
Log (D0/h), f, and β found by Flynn for 90 drugs79 were -2.72, 0.71 and 0.0061 respectively.  
The diffusivity of these charged complexes is higher than expected and f is similar as the charge 
of the complex has a similar effect on the octanol and membrane partitioning.  This further 
supports the conclusion that for a labile drug and its complexes, factors other than size and 
partition coefficient are significant. 
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4.5 Conclusion 
The amount of ISO transferred from aqueous solution to organic layer changes with pH and 
with the presence of different metal ions. The result showed that ISO, as well as the metal 
complexes under study, had log Poct/aq values below zero, indicating that the ligand and the 
complexes are hydrophilic. The presence of metal greatly enhanced the permeation of ISO 
through an artificial membrane in the order Cu(II) > Zn(II) > Ni(II) > ISO. Statistical analysis 
of the results showed that there was no correlation between the logarithm of partition and 
permeability coefficients. This implies that log Poct/aq is not as good a measure of absorption of 
ISO as log Kp. 
The log Poct/aq values for RFN and its complexes are all positive indicating that they are all 
lipophilic. The comparison of the permeability coefficients of the ligands reveals that RFN, 
which is the most lipophilic, is the least permeable. This might be attributed to the fact that 
RFN was entrapped within the membrane hindering the diffusion through the membrane. 
However, the incorporation of Cu(II) reduced log Poct/aq and enhanced the permeability of RFN 
through the membrane. 
The values of the partition coefficients for PAS and its complexes, are positive, indicating that 
they are lipophilic. The influence of the metal on the flux and the permeability coefficient of 
the ligand through the Cerasome 9005 membrane shows that Zn(II) was able to improve the 
bioavailability of p-aminosalicylic acid with an enhancement ratio of 2.  However, Cu(II) and 
Ni(II) do not have any effect on the absorption since the values of the diffusion flux as well as 
the permeability coefficient are close to those obtained when the metal was not incorporated 
into the system. The statistical value also indicates that there is no correlation between the two 
measured parameters since the correlation factor is very much less than 1. 
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The partition coefficients for PZA and its complexes are all below 0 and are considered low 
lipophilic. The permeability coefficient Kp for the ligand alone and those of its metal complexes 
were similar. The presence of the metal does not affect the flux and permeability coefficient of 
PZA. The statistical analysis indicates that there is no correlation between the logarithm of 
partition coefficient and permeability coefficient of PZA. 
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Chapter 5 
 
Solid-state studies 
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5.1 Introduction 
This chapter presents an account of the attempted synthesis and characterisation of solid 
isoniazid (ISO) and pyrazinecarboxamide (PZA) metal complexes. As described in a previous 
chapter, the equilibria involving the formation of metal complexes of isoniazid, ethambutol 
(EMB) and p-aminosalicylic acid (PAS) in solution have been studied using glass electrode 
potentiometry (GEP), and structures have been proposed based on the model. The metal 
complexes of rifampicin and pyrazinecarboxamide could not be explored because the pKa 
values were below the pH range of our studies. To confirm the models proposed for the Cu-
complexes of ISO, EMB and PAS, UV-Visible spectroscopy was carried out.  
The permeability and the lipophilicity characteristics of the ligands with Cu(II), Ni(II) and 
Zn(II) ions have also been studied in previous chapters. To establish the structures of the stable 
complexes, an attempt was made to synthesise and characterise the complexes in solid form 
for X-ray diffraction studies. Various methods were employed in the synthesis, including co-
precipitation, recrystallization and mechanochemistry (both co-grinding and liquid-assisted 
grinding (LAG)).  Mechanochemistry is the synthesis of chemical compounds using 
mechanical force.1 It has been employed in organic synthesis and has provided a solvent-free 
path in reactions involving oxidation and reduction, as well as Wittig condensation and Suzuki 
Coupling.2  Ondruschka and co-workers3 and Bolm and co-workers4 have proved that the 
solvent-free reactivity in mechanochemical synthesis in a planetary mill allows substantial 
improvement in energy efficiency, compared to a conventional solution-based or microwave-
assisted synthesis. Mechanochemistry has also been used in the areas of molecular co-crystals 
and metal-organic materials. The LAG method has also been recognised as a highly efficient 
and rapid method for co-crystal screening. LAG uses a sub-stoichiometric amount of a liquid 
phase to enable, accelerate and template self-assembly reactions including solid, liquid or 
130 
 
gaseous reactants. The mechanochemical method is solvent-free and environmentally friendly. 
The products obtained in the present study through mechanochemistry were monitored using 
the PXRD technique. However, they were all found to be physical mixtures of the starting 
materials. 
In an attempt to synthesise isoniazid and pyrazinecarboxamide (pyrazinamide) metal 
complexes via the solvothermal method, intriguing crystalline phases were obtained, quite 
different from those expected. The techniques listed below were used to characterise the crystal 
structures obtained.   
5.2 Methodology 
5.2.1 Elemental analysis 
Elemental analysis experiments were performed on a Fisons EA1108 CHNS-O Elemental 
Analyzer to determine the percentage of carbon, hydrogen and nitrogen present in the samples. 
The results were used as a basis for interpreting Fourier electron density maps obtained from 
single crystal X-ray diffraction.  
5.2.2 X-ray Diffraction 
5.2.2.1 Single crystal X-ray diffraction 
Excellent single crystals of selected complexes were prudently chosen to perform single crystal 
X-ray diffraction. Crystals were removed from their mother liquor and immediately covered 
with Paratone N oil (Exxon Chemical Co., TX, USA) to avoid loss of solvent molecules or 
decomposition. A single crystal was chosen under a microscope and attached to a nylon loop 
linked to a rigid mounting. Where single crystals were large, they were cut to obtain a suitable 
size. This was followed by mounting the nylon loop on the goniometer head under a cold stream 
of nitrogen gas. Single crystal data-collections were performed on a Bruker Kappa Apex II Duo 
131 
 
diffractometer using MoKα radiation (λ = 0.71073 Å).  X-rays were produced by a Bruker K780 
generator powered at 50 kV and 30 mA. 
Data-collection was carried out at low temperature [173(2) K] using a Cryostream cooler 
(Oxford Cryosystems, UK) at a nitrogen vapour flow rate of 20 cm3 min-1. Unit cell refinement 
and data reduction, including Lorentz-polarization corrections, were carried out using the 
program SAINT.5 The program SADABS6 was used to correct absorption effects on all 
intensity data. 
For each structure, the space group was determined from systematic absences in the X-ray 
intensity data. The program XPREP7 was used to confirm the space group. This program 
prepares the input file which is then used for structure solution by direct methods using the 
SHELXS program.8   All non-hydrogen atoms were refined by full-matrix least-squares on F2 
with anisotropic thermal parameters using SHELXL-978 within the X-Seed interface.9 All H 
atoms were initially located in difference electron density maps and were added to the model 
in idealised positions in a riding model with isotropic thermal parameters having values in the 
range 1.2-1.5 times those of their parent atoms.  The program PovRay in the X-Seed interface 
was used to generate the figures.10 
5.2.2.2 Powder X-ray diffraction (PXRD) 
The experiments were performed on a Bruker D8 Advance diffractometer equipped with a 
Lynxeye detector using CuK𝛼1-radiation (λ =1.5406 Å) at 294 K (21 
°C). Samples were ground 
into a fine powder after drying on a filter paper and placed on a zero-background sample holder 
and scanned over the 2θ range 4° to 40° with 0.015° increments. X-rays were generated by a 
current flow of 40 mA and an accelerating voltage of 30 kV. A receiving slit of 0.6 mm and 
primary and secondary slits of 2.5 mm were used. 
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5.3 Fourier transform infrared (FTIR) spectroscopy 
When a complex can be isolated as a solid, vibrational spectroscopy, which includes IR can be 
used to identify the coordinating groups. IR gives detailed geometrical information from 
normal coordinate analysis of the data.11 It uses an empirical analysis based on the comparison 
of structures of known metal-ligand complexes. Whenever stable complexes are prepared, it is 
standard practice to acquire an IR spectrum, since it is possible to determine the chelating 
groups by studying shifts of the ligand-based absorption peaks from their positions in the ligand 
itself.  For example, metal-nitrogen bonding has been investigated in several diazepam 
complexes using FTIR spectroscopy.12 IR studies were carried out on a Bruker Alpha 
spectrometer equipped with an ATR platinum Diamond reflectance accessory for solid 
samples. The samples were scanned over a range of 400-4500 cm-1.  
5.4. UV- Vis Spectroscopy 
For each of the complexes whose structures were determined in this study, a 2×10-5 M solution 
was prepared in ethanol. The absorbances of these solutions were measured with a Hewlett 
Packard 8452A Diode Array spectrophotometer from 200 nm to 800 nm.  A blank was used to 
correct the absorbance. The wavelength of maximum absorption was determined from the plot 
of absorbance against wavelength (nm). 
5.5. Attempted synthesis of a Cu-isoniazid complex 
5.5.1 Synthesis  
In the synthesis 0.0137 g (1.0 mmol) of isoniazid (ISO, C6H7N3O) was dissolved in 6 ml of 
ethanol-water (1:1 v/v) mixture and 0.0085 g (0.5 mmol) of CuCl2.H2O was dissolved in 6 ml 
of water. The mixture of the two solutions was placed in a Teflon cup and heated in an 
autoclave at 100 °C for two days. The coloured solution was maintained at room temperature 
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for three days, and subsequently, blue crystals suitable for X-ray diffraction were filtered off. 
Elemental analysis yielded the following: C, 38.0%; H, 4.05%; N, 5.83%. From these data, it 
was not possible to arrive at a complex formula consistent with the above reactants. Further 
analytical techniques were carried out to ascertain the nature of the product. The synthesis was 
initially carried out in aqueous media to emulate the solution studies. Unfortunately, crystals 
were not obtained. This prompted the use of the alcoholic media employed in the synthesis.  
 
5.5.1.1 X-ray data and structure determination  
A blue crystal of dimensions 0.020 × 0.070 × 0.140 mm was mounted on a nylon cryoloop in 
a random orientation. The determination of the unit cell and data-collection were performed on 
a Bruker Kappa Apex II Duo diffractometer using graphite-monochromated MoK radiation 
(λ = 0.71073 Å). 1673 independent reflections (Rint = 0.061) were obtained after merging all 
the intensity data collected at 173 K. Analysis revealed that the compound belongs to the 
triclinic system, space group P1. The structure was solved by direct methods using the 
SHELXS program. Instead of the expected presence of the isoniazid molecule in the complex, 
the metal ion was found to be coordinated to isonicotinate ions, thus indicating that the original 
drug had been hydrolysed during complex synthesis. (The details of the chemical 
transformation accompanying the synthesis are discussed in a subsequent section). Phenyl H 
atoms were placed in idealised positions but H atoms of water molecules were allowed to refine 
freely. The refinement converged with R1 = 0.0469, wR2 = 0.1175. A full listing of the crystal 
data and refinement details appears in Table 1. On comparing these data with Cu(II) structures 
deposited in the Cambridge Structural Database (CSD),13 they were found to be very similar to 
those reported previously for the hydrated copper(II)isonicotinate complex 
Cu(ISONIC)2(H2O)4.
14 
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Table 5.1: Crystal data and details of refinement. 
Compound Cu(ISONIC)2(H2O)4 Cu(ISONIC)2(H2O)4 
Previously reported14 
Formula 
Molecular weight (g mol-1) 
Crystal system 
Space group 
a (Å) 
b (Å) 
c (Å) 
α (o) 
β (o) 
γ (o) 
V (Å3) 
Z 
No. of reflections collected 
 Calculated density (g cm-3) 
µ(MoKα) [mm-1] 
F(000) 
Temperature (K) 
Crystal size (mm) 
X-ray wavelength (Å) 
ϴ-range (ᵒ) 
Dataset 
Total, Unique data, R(int) 
Observed data [I > 2σ(I)] 
Nref, Npar 
R1, wR2, S 
(∆/σ) mean  
(∆ρ) min, max (eÅ-3) 
C12H16CuN2O8 
379.82 
Triclinic 
           P1 (No. 2) 
6.3124(15) 
6.8226(15) 
9.1702(19) 
99.111(4) 
105.144(4) 
108.558(4) 
348.58(13) 
1 
1673 
1.809 
1.614 
195 
173 
0.020 × 0.070 × 0.140 
Mo Kα (0.71073) 
2.4, 28.0 
-8: 8; -8: 9; -12:12 
7370, 1673, 0.061 
1477 
1673, 122 
0.0469, 0.1175, 1.05 
< 0.001 
-1.02, 1.16 
 
C12H16CuN2O8 
379.82 
Triclinic 
                   P1 
6.3334(3)a 
6.8871(3) 
9.1807(4) 
99.433(4) 
105.190(4) 
108.213(4) 
353.7(1) 
1 
1528 
1.783 
1.590 
195 
298 
0.3 × 0.5 × 0.1 
0.71069 
-b 
8, 7, 11  
1528, 1358, - 
- 
1358, 138 
0.0350, 0.052, - 
- 
-, - 
aThe order in which the unit cell parameters were originally reported was different                                                      
bThe dash (-) in column three indicates that the corresponding parameter was not explicitly reported in the paper 
The crystal data and details of refinement reported in the literature14 refer to a temperature of 
298 K, whereas the data reported in the present structure re-determination were collected at a 
lower temperature of 173K. The molecular structure is depicted in Figure 5.1.  
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Figure 5.1: The molecular structure of Cu(ISONIC)2(H2O)4 with atomic labelling and thermal 
ellipsoids of the non-H atoms drawn at the 50% probability level. 
 
The coordination environment shows that the Cu(II) ion coordinates with two isonicotinate 
ligands and four water molecules resulting in a distorted octahedral configuration of CuN2O4 
type. The isonicotinate ions and water molecules both act as monodentate ligands via the 
pyridine nitrogen and the oxygen atoms respectively. The Cu atom is located on a centre of 
inversion.   
 The bond distances obtained from PLATON15 for Cu-O1 and Cu1-O4 are 1.984(3) Å and 
2.426(3) Å respectively. Hence, the coordination around the Cu(II) atom shows an axially-
elongated octahedral geometry with Jahn-Teller distortion. The Cu1-O4 bond distance lies in 
the range (2.275-2.520 Å) reported for Cu(II) complexes with Jahn-Teller distortion, and the 
equatorial bond distance (Cu1-O1) is slightly longer than those reported for six-coordinated 
Cu(II) complexes with water molecules (1.950-1.973 Å).14 The CuN distance (1.989(2) Å) is 
shorter than those reported for six-coordinated Cu(II) complexes with pyridine ligands (2.039-
2.055 Å).13-14 Selected bond lengths and angles are summarised in Table 5.2. 
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Table 5.2:  Selected bond lengths (Å) and angles () for Cu(ISONIC)2(H2O)4. 
Bond lengths (Å) Bond Angles (°) Bond Angles (°) 
Cu1 – O1          1.984(3) 
Cu1 O4          2.426(3) 
Cu1  N1          1.989(2) 
N1  C1            1.391(3) 
N1  C5            1.392(4) 
C1  C2            1.395(3) 
C2  C3            1.392(4) 
C3  C4            1.393(3) 
C4  C5             1.397(3) 
O5  C6            1.258(5) 
O6  C6           1.252(5) 
    
O1  Cu1  O4                93.0(1) 
 O1  Cu1  O4i               86.1(1) 
 N1  Cu1 O1                90.4(1) 
        O1  Cu1 N1                89.6(1) 
        O4  Cu1  N1               88.8(1) 
  Cu1  N1  C1              118.9(2) 
  Cu1  N1  C5              121.9(2) 
        N1  C1  C2                120.7(2) 
        C1  C2  C3                119.6(2) 
    
   
  C2  C3  C4                  120.3(2) 
  C2  C3  C6                  119.5(2) 
  C4  C3  C6                  120.2(3) 
  C3  C4  C5                  119.4(2) 
  N1  C5  C4                  120.8(2) 
  O5  C6  C3                  116.1(3) 
  O5 C 6  O6                  125.8(3) 
  O6  C6   C3                 118.1(3) 
 
 
 
 
The six atoms form an octahedral array around the copper ion, the angle O1-Cu1- O1i (i = 1 - 
x, 1 - y, 1 – z) is 180° due to centrosymmetry and O1CuN1 is 89.6(1)° (Table 5.2). All water 
H atoms engage in intermolecular hydrogen bonding (Table 3). The OHO hydrogen bonds 
are crucial and contribute to the stability of the crystal structure.  
Table 5.3: Hydrogen bond data (distances in Å, angles in degrees) for Cu(ISONIC)2(H2O)4. 
D-H---A d(D-H) d(H---A) d(D---A)  (DHA) 
O4H3O6iv 0.88(6) 2.04(6) 2.896(4) 167(5) 
O4-H6O5iii 0.78(6) 2.06(6) 2.825(5) 167(5) 
O1H7O5ii 0.72(6) 1.90(6) 2.615(4) 178(11) 
O1H8O6i 0.77(5) 1.98(5) 2.736(4) 168(6) 
C1H1O4 0.95 2.60 3.068(4) 111 
C5H5O1v 0.95 2.48 3.352(4) 154 
Symmetry operations: (i) 1- x, 1- y, 1- z; (ii) -1+ x, y, -1+ z; (iii) -x, -y, 1- z; (iv) 1 - x, -y, 1- z; (v) 1+ x, y, z 
A packing diagram of Cu(ISONIC)2(H2O)4 is shown in Figure 5.2. The oxygen atoms of the 
carboxylate groups are acceptors of intermolecular hydrogen bonds from the coordinated water 
molecules of the neighbouring [Cu(ISONIC)2(H2O)4] molecules to form three-dimensional 
supramolecular complexes. As shown in Figure 5.2, molecules are interconnected in the solid 
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state by five crystallographically unique intermolecular hydrogen bonds, generating a final 
three-dimensional supramolecular network.  
 
Figure 5.2: Packing diagram illustrating principal H-bonds in Cu(ISONIC)2(H2O)4. 
 
5.5.1.2 PXRD Data 
To further confirm that the complex isolated in the present study was the same phase as that 
reported previously, the experimental PXRD pattern of the former was compared with that 
calculated from the single crystal X-ray data reported for Cu(ISONIC)2(H2O)4.
14 These powder 
patterns (Figure 5.3) are very similar, with corresponding peaks observed at 2 values 10.2, 
15.2, 16.9, 18.9, 19.7, 23.3, 26.8 and 27.8, thus revealing that these represent the same crystal 
phase and therefore supporting the inference from the single crystal X-ray diffraction study 
that during complex synthesis the isoniazid component had been chemically transformed to the 
isonicotinate ion. 
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Figure 5.3: Experimental PXRD trace for the complex isolated in the present study and the simulated 
PXRD trace for Cu(ISONIC)2(H2O)4.14 The abnormally high intensity of the peak at 15.2 
in the experimental trace is attributed to preferred orientation of crystallites in the sample. 
Small differences in peak angular positions are due to the different temperatures of the two 
analyses. 
 
5.5.1.3. Infrared Spectral Data 
The IR spectrum of the compound (Figure 5.4) was recorded using a Bruker Alpha 
spectrometer equipped with an ATR Platinum Diamond reflectance accessory for solid 
samples. Samples were scanned over a range of 400-4000 cm-1  and the results are presented in 
Table 5.4.   
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Figure 5.4: The IR spectrum of Cu(ISONIC)2(H2O)4. 
 
The frequencies and assignments of spectral bands for ISONIC and its copper complex are 
shown in Table 5.4. The carboxylate stretching vibration in Cu(ISONIC)2(H2O)4 is dependent 
on the coordination mode to the copper(II) ion.16  
Table 5.4: The frequencies (in cm-1) and assignments of vibrations of ISONIC and its complex. 
 Isonicotinate ion in sodium 
isonicotinate16 
Cu(ISONIC)2(H2O)4 Assignments 
- 3410(br) (OH) 
3070(vw) 3082(w) (CH)ar 
1584(w) 1585(w) (C=C)ar 
1534(s) 1538(s) as(COO-) 
1410(s) 1383(s) s(COO-) 
1217(w) 1235(s) (CO) + δ(OH) 
1058(w) 1061(w) δ(CCH) 
848(s) - (COO-)s 
764(s) 775(s) (CCH)ar 
679(s) 702(s) δ(COO-) 
- 667 (CuO) 
124 155 (as-s)  
 
The broad band at 3410 cm-1 may be attributed to (OH) absorption in H2O molecules. The 
CuO stretching frequency is observed at 667 cm-1 in the complex and agrees with the 
observations of former workers.17 
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5.4. Attempted synthesis of a Cu – pyrazinecarboxamide complex 
5.4.1. Synthesis 
A mass of 0.0369 g (1.0 mmol) of pyrazinecarboxamide (PZA, C5H5N3O) was dissolved in 5 
ml of methanol and 0.0256 g (0.5 mmol) CuCl2.H2O was dissolved in 3 ml of ethanol. The 
mixture of the two solutions was placed in a Teflon cup and heated in an autoclave at 100 C 
for two days. Elemental analysis of the resulting crystals indicated C10H6CuN4O4 as the 
formula of the compound (Anal. Calc. C10H6CuN4O4:  C: 38.8%; H, 2.0%; N, 18.1%. Found 
C, 37.33%; H, 1.90%; N, 18.13%). It is evident from the data above that during the synthesis 
a complex with a different number of nitrogen atoms from that expected based on the formula 
of PZA resulted. Further analytical techniques were carried out to ascertain the nature of the 
complex. Details of X-ray data-collection and structure refinement of the complex are shown 
in Table 5.5. A blue crystal of dimensions 0.08 × 0.09 × 0.11 mm was mounted on a nylon 
cryoloop which was placed on the goniometer head under a cold stream of nitrogen gas.  
Analysis of the structure revealed that the complex belongs to the monoclinic system with 
space group P21/c. X-ray structure determination revealed that the product was in fact catena-
[bis(2-pyrazine-2-carboxylato)-copper(II)], with codename Cu(PZONIC)2 where PZONIC is 
the 2-pyrazine carboxylate ion, instead of the expected Cu-pyrazinecarboxamide complex. The 
mechanism for the formation of this unexpected product is discussed later. It was subsequently 
discovered that the crystal structure of the same crystalline phase had been reported previously 
in the Cambridge Structural Database (CSD) with refcode BEYPUQ02,17-18 intensity data 
having been collected at 283-303 K, while in the present study the crystal was analysed at 
173(2) K.   
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Table 5.5: Crystal data and details of refinement. 
Compound Cu(PZONIC)2 Cu(PZONIC)2  
Previously reported18 
Formula 
Molecular weight (g mol-1) 
Crystal system 
Space group 
a (Å) 
b (Å) 
c (Å) 
α (o) 
β (o) 
γ (o) 
V (Å3) 
Z 
No. of reflections collected 
Calculated density (g cm-3) 
µ(MoKα) [mm-1] 
F(000) 
Temperature (K) 
Crystal dimensions (mm) 
X-ray wavelength (Å) 
ϴ -range (o) 
Dataset 
Total., Unique data, R(int) 
Observed data [I>2σ(I)] 
Nref, Npar 
R1, wR2, S 
(∆ /σ) mean 
∆ρmin, max (eÅ-3) 
C10H6N4O4Cu 
309.7 
Monoclinic 
P21/c 
5.024(6) 
15.309(2) 
7.020(1) 
90 
106.188(3) 
90 
518.62(1) 
2 
1302 
1.984 
2.124 
310 
173(2) 
0.08 × 0.09 × 0.11 
MoKα (0.71073 Å) 
2.7, 28.4 
-6: 6; -20: 20; -9: 9 
11494, 1302, 0.056 
1078 
1302, 88 
0.0305, 0.0821, 1.05 
< 0.001  
-0.48, 0.38 
C10H6N4O4Cu 
309 
Monoclinic 
P21/c 
5.034(4) 
15.332(13) 
7.0720(6) 
90 
106.6250(10) 
90 
523.49(8) 
2 
2928 
1.965 
- 
310 
291(2) 
0.12 ×0.10 × 0.08 
(0.71073 Å) 
- 
- 
- 
- 
- 
0.0214, 0.0678, 1.020 
- 
- 
The dash (-) in column three indicates that the corresponding parameter was not explicitly reported in the paper 
 
The molecular structure of Cu(PZONIC)2, the coordination environments around Cu(II) centres 
and the atom labelling of the complex are shown in Figure 5.5. The complex displayed a square-
planar geometry, with the ligand acting in a bidentate mode.  Metal ion coordination is effected 
via the pyrazine nitrogen atoms and carboxylate oxygen atoms of the pyrazine carboxylate 
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resulting in the formation of five-membered chelate rings.  The Cu(II) ion is located on a centre 
of inversion. 
 
Figure 5.5: The molecular structure of Cu(PZONIC)2 with atomic labelling and thermal ellipsoids of 
the non-H atoms drawn at the 50% probability level. 
      
The largest single contribution to the distortion from square-planar geometry is shown by the 
O2CuN10 angle (83.80(7)), resulting from the formation of the five-membered ring 
required at the metal atom by the bidentate ligand.  
The coordination geometry at the metal centre is in fact distorted octahedral, and the structure 
is polymeric, as shown in Figure 5.6.  Selected bond lengths and angles are listed in Table 5.6. 
 
Figure 5.6: A short segment of a polymeric unit of Cu(PZONIC)2. 
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The copper ion in Cu(PZONIC)2 is hexa-coordinate. The axial coordination is due to the weak 
coordination of the copper ion with a carboxylate oxygen atom of the neighbouring molecule, 
thus forming a distorted-octahedral coordination sphere. The Cu1O4 coordination distance of 
2.703(2) Å is considerably longer than the usual carboxylate oxygen to copper distance of 
1.94(1) Å.19 The coordination distances Cu1-N10 and Cu1-O2 (1.977(2) and 1.935(2) Å) are 
comparable with those reported for Cu(II) complexes.20-22  
Table 5.6:  Selected bond lengths (Å) and angles () for Cu(PZONIC)2.  
         Bond lengths (Å) Bond Angles (°) Bond Angles (°) 
Cu1  O2          1.935(2) 
Cu1  O4          2.703(2) 
Cu1  N10       1.977(2) 
N7  C6            1.333(3) 
N7   C8           1.333(4) 
N10  C5          1.340(3) 
N10  C9          1.336(3) 
O2  C3            1.283(3) 
O4  C3            1.226(3) 
C5  C6            1.386(3) 
O2  Cu1  N10         83.80(7) 
O2  Cu1 O4(i)         92.47(6) 
 O4  Cu1 O2(ii)        87.53(6) 
      O4  Cu1 N10          87.68(7) 
 N10  Cu1 O4          92.32(7) 
  N10 Cu1O2            96.20(7) 
 C6  N7 C8              116.8(2) 
 C5  N10  C9          118.6(2) 
 Cu1  N10  C5         111.3(2) 
 Cu1  N10  C9         130.1(2) 
 
Cu1 O2  C3            114.9(2) 
C3  O4  Cu1           101.5(2) 
O2  C3  C5            114.7(2) 
      O4  C3  C5            119.6(2) 
O2  C3  O4            125.6(2) 
      N7  C6  C5            121.6(2) 
N10  C5  C3          114.9(2) 
N7  C8  C9            122.8(2)                                                                                                
N10  C9 - C8            119.4(2) 
 
Symmetry operations: (i) -1+ x, y, z; (ii) - x, 1- y, 1- z 
 
The average conjugated CC bond distance 1.386(3) Å and the average CN bond distance 
1.333(3) Å compare favourably with the respective known literature values23 (1.396 and 1.334 
Å) while the average endocyclic N-C-C angle, 121.6(2),  is similar to the evalue 122.4(1) 
previously reported for pyrazine carboxylic acid in the literature.24 The partial packing diagram 
illustrating principal H-bonds (C-HO, C-HN) in Cu(PZONIC)2 is shown in Figure 5.7. 
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Figure 5.7: Layer formation based on hydrogen bonds (CHO, CHN) in Cu(PZONIC)2. 
The hydrogen bond lengths and angles for the compound are shown in Table 5.7.  
Table 5.7: Hydrogen bond data (distances in Å, angles in degrees). 
DHA d(D-H) d(HA) d(DA) (DHA) 
C6H6O4i 0.95 2.32 3.259(3) 168 
C8H8O4ii 0.95 2.50 3.388(3) 155 
C9H9N7iii 0.95 2.54 3.458(3) 161 
Symmetry operations: (i) 2 -x, 1 - y, 2 - z; (ii) 1 - x, -1/2 + y, 3/2 - z; (iii) -1 + x, ½ - y, -1/2 + z 
 
5.4.1.2 PXRD Data 
Figure 5.8 shows the PXRD pattern obtained from the experimental sample prepared in the 
present study and the calculated pattern of the complex structure reported in the literature.17 
There are some intensity differences that can be attributed to preferred orientation effects in 
the experimental sample, but the otherwise high level of agreement between the two traces is 
convincing evidence of the identity of the two phases. 
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Figure 5.8: Experimental PXRD trace for the complex isolated in the present study and the simulated 
PXRD trace for Cu(PZONIC)2.18  
5.4.2 Infrared Spectral Data 
Fourier transform infrared (FTIR) spectroscopy was conducted to determine whether the 
spectral observations were consistent with the crystal structure. A shift of a band to a lower 
wavelength is anticipated if the carboxylate functional group is coordinated to the metal. The 
IR spectrum and the frequencies as well as the band assignments for Cu(PZONIC)2 are shown 
in Figure 5.9 and Table 5.8 respectively.   
 
Figure 5.9: The IR spectrum of Cu(PZONIC)2.  
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Table 5.8: The frequencies (cm-1) and assignments of bands in the FTIR spectra of PZONIC and    
Cu(PZONIC)2.                        
Pyrazinoate ion (PZONIC) in 
[Ni(PZONIC)2(H2O)2]25 
Cu(PZONIC)2 Assignment 
1585(s) 1581 (C=N) 
1660(s) 1642 (C=O) 
1290(s) 1297 (C-O) 
- 454 (Cu-O) 
- 537 (Cu-N) 
 
For the Cu(PZONIC)2 the sharp band centred at approximately 1581 cm
-1 can be ascribed to  
(C=N). The bands at 1642 cm-1 and 1297 cm-1 are assigned to (C=O) and (C-O) 
respectively, which are consistent with monodentate carboxylate coordination. The presence 
of a sharp band at 537 cm-1 also confirms the assignment of the (Cu-N) mode.26  
5.4.3 UV-Visible spectroscopy 
The UV-spectrum of Cu(PZONIC)2 in ethanolic solution is shown in Figure 5.10. The spectrum 
displays bands between 200 and 350 nm. The band at 270 nm is ascribed to the π→π* transition 
and the peak at 328 nm is ascribed to the n→π* transition of the pyrazine ligand.27  
 
Figure 5.10: UV-Visible spectrum for Cu(PZONIC)2 in ethanol.   
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5.5 Attempted Synthesis of Ni2+ and Zn2+-Pyrazinecarboxamide Complexes. 
Due to the demand on the chemical industry to manage the global problem of pollution and the 
growing energy crisis, there is a need to develop preparative processes that are less expensive 
and more environmentally friendly. The process of co-grinding reactants using a mortar and 
pestle provided a solvent-free and hence more ‘green’ technique for attempted metal complex 
formation. A mass of 0.0369 g (1.0 mmol) of pyrazine-carboxamide (PZA) was weighed, and 
the following amounts of the metal salts were weighed: 0.0275 g (0.5 mmol) Zn(CH3COO)2 
and 0.0265 g (0.5 mmol) Ni(CH3COO)2. The PZA and each of the metal salts were co-ground 
without solvent addition using a mortar and pestle for 4 min, after which the PXRD pattern of 
the product was monitored. Further sampling and PXRD recording were performed after 
consecutive periods of 10 min and 20 min to ensure that any reaction that might have occurred 
had reached completion. The same experiments were performed using the liquid-assisted 
grinding (LAG) technique with ethanol as solvent, followed by recording of product PXRD 
traces. However, all products were found to be physical mixtures of the starting materials. The 
solvothermal method was therefore used in an attempt to form the desired complexes, as 
described below.  
A mass of 0.0369 g (1.0 mmol) of pyrazinecarboxamide was weighed and dissolved in 5 ml of 
methanol. Two separates 3 ml ethanolic solutions containing respectively 0.0275 g (0.5 mmol) 
Zn(CH3COO)2 and 0.0265 g (0.5 mmol) Ni(CH3COO)2 were prepared. The PZA solution was 
mixed with each of the metal salt solutions and the two resulting solutions were placed in 
Teflon cups and heated in an autoclave at 100 ℃ for two days. Crystals were formed and 
analysed. Elemental analysis data for the complexes are shown in Table 5.9. 
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Table 5.9: Elemental analysis data for the attempted synthesis of Ni2+ and Zn2+-pyrazine- 
carboxamide complexes.  
Complexes Calculated % 
 C           H            N 
Experimental % 
C           H            N 
C10H10N4O6Ni 35.22       2.94       16.43 35.05      2.75        16.18 
C10H10N4O6Zn 34.54       2.87       16.10 34.49      2.76        16.09 
  
During the synthesis, complexes with a different number of nitrogen atoms from that expected 
based on the formula of PZA resulted. Thus, other analytical techniques were carried out to 
establish the nature of the complexes. From single crystals of each of the above complexes, the 
respective unit cell parameters were measured on the diffractometer and compared with those 
found for complexes listed in the Cambridge Structural Database (CSD) having similar unit 
cell parameters. The latter complexes turned out to be the same metal complexes as those 
reported in the present study, namely diaqua-bis(2-pyrazinecarboxylato)-M(II) complexes, 
where M = Ni and Zn. The comparative data are listed in Table 5.10.  It should be noted that 
the unit cell parameter estimates for the compounds of the present study were determined and 
refined using a limited number of CCD detector frames only since full X-ray data-collections 
were not intended, whereas unit cell data for the compounds cited from the literature are more 
accurate, but span a large temperature range. Despite these different conditions, the level of 
agreement confirms that the respective crystalline phases reported in this study and those listed 
in the CSD are the same. Furthermore, this series of metal complexes appears to be isostructural 
from the near equality of the corresponding unit cell parameters, common space group and Z 
value. 
Since pyrazinecarboxamide (PZA) was employed in the attempted solvothermal syntheses of 
the present study and the products in fact contain the 2-pyrazinecarboxylato ligand, it is evident 
that an undesired chemical transformation had occurred. As described earlier in this chapter, 
149 
 
the analogous transformation occurred when the solvothermal synthesis of the copper complex 
of PZA was attempted.    
Table 5.10:  Comparative crystal data for M(PZONIC)2(H2O)2 complexes. 
Compound Ni(PZONIC)2(H2O)2 
Present study 
Ni(PZONIC)2(H2O)228 Zn(PZONIC)2(H2O)2 
Present study 
Zn(PZONIC)2(H2O)229 
Formula 
Molecular weight (g mol-1) 
Crystal system 
Space group 
a (Å) 
b (Å) 
c (Å) 
α (o) 
β (o) 
γ (o) 
V(Å3) 
Z 
Temperature (K) 
 
C10H10N4O6Ni 
340.93 
Monoclinic 
P21/c 
5.302 
11.032 
10.346 
90.00 
99.00 
90.00 
597.70 
2 
173(2) 
C10H10N4O6Ni 
340.93 
Monoclinic 
P21/c 
5.250(1) 
10.992(1) 
10.285(1) 
90.00 
99.80 
90.00 
584.894 
2 
283-303 
C10H10N4O6Zn 
347.38 
Monoclinic 
P21/c 
5.155 
10.998 
10.137 
90.00 
99.00 
90.00 
567.64 
2 
173(2) 
C10H10N4O6Zn 
347.38 
Monoclinic 
P21/c 
5.2516(1) 
11.1098(3) 
10.2151(3) 
90.00 
99.817(1) 
90.00 
587.265(3) 
2 
153(2) 
 
5.5.1 Infrared Spectral Data 
The infrared spectra and the assignments based on the frequencies for the above complexes of 
PZONIC are shown in Figure 5.11 and Table 5.11.  
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Figure 5.11: The IR spectra of M(PZONIC)2(H2O)2 complexes. 
The close resemblance in the spectra of the two complexes is consistent with their established 
crystal isostructurality. 
Table 5.11: FTIR frequencies in (cm-1) and assignments for M(PZONIC)2(H2O)2 complexes 
Pyrazinoate ion 
(PZONIC) in 
[Ni(PZONIC)2(H2O)2]25
 
Ni(PZONIC)2(H2O)2 
(present study) 
Zn(PZONIC)2(H2O)2 
(present study) 
Assignment 
3425 3213 3243 (OH)  
1585(s) 1586 1585 (C=N) 
1660(s) 1621 1623 (C=O) 
1290(s) 1289 1291 (C-O) 
- 466 455 (M-O) 
- 626 604 (M-N) 
 
Comparison of the IR spectrum of free pyrazinoic acid25 with the spectra of the 
Ni(PZONIC)2(H2O)2 and Zn(PZONIC)2(H2O)2 complexes of the present study reveals that on 
metal complexation considerable changes in frequencies have occurred which can determine 
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the coordination sites in chelation. The frequencies (C=N), (C=O) and (C-O) for the Ni and 
Zn complexes are very similar to those listed in Table 5.8 for the corresponding vibrations in 
Cu(PZONIC)2, with analogous implications for the mode of ligand coordination. For the Ni 
and Zn complexes, the broad band spanning the approximate range 3200 – 3400 cm -1 is 
ascribed to the vibration of OH in the included water molecules.25,30 To further support bond 
formation between the metal and N- and O-donors of the ligand,31-33 some moderately intense 
bands appear in the 400-600 cm-1 region and can be assigned to (M-N) and (M-O) [M = Zn, 
Ni] vibrations.  
5.5.2. PXRD    
The PXRD patterns of the Ni(PZONIC)2(H2O)2 and Zn(PZONIC)2(H2O)2 crystals obtained 
from the solvothermal syntheses were compared with the respective simulated patterns 
calculated from the literature data in Figures 5.12 and 5.13. In each case there is very good 
agreement between experimental and simulated traces. Furthermore, the close resemblance 
between the PXRD traces of Ni(PZONIC)2(H2O)2 and Zn(PZONIC)2(H2O)2 confirms their 
isostructurality, which had been inferred from a comparison of their unit cell data obtained 
from single-crystal XRD.  
 
Figure 5.12: Experimental PXRD trace for the complex isolated in the present study and the simulated 
PXRD trace for Ni(PZONIC)2(H2O)2.28 
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Figure 5.13: Experimental PXRD trace for the complex isolated in the present study and the simulated 
PXRD trace for Zn(PZONIC)2(H2O)2.29    
5.6 Rationalisation of isolation of unexpected products 
The unexpected products obtained in the attempted syntheses of metal-PZA complexes can be 
attributed to the hydrolysis of PZA to pyrazinoic acid under the harsh reaction conditions 
employed, namely using the solvothermal method. A similar result was reported when pure 
PZA was reacted with a water-methanol solution of copper(II) acetate in the presence of 3-
nitrobenzoic acid (Figure 5.14), after removal of the initially-produced by-product Cu(3-
NO2bz)2(H2O)2 (bz = 3,5-dinitrobenzoate).
22  
 
Figure 5.14: Catalytic hydrolytic reaction of pyrazinecarboxamide to pyrazine carboxylate.22 
 
An analogous hydrolytic reaction was reported to have occurred when pyridine-2-carboxamide 
underwent prolonged reflux in water in the presence of Cu(II) ions.21   
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Furthermore, based on the results from our attempted solvothermal synthesis of a Cu-isoniazid 
complex, where the product unexpectedly contained the isonicotinate ion, we infer that 
analogous hydrolysis had occurred in that case. 
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5.6 Conclusion 
This chapter provides a summary of the results obtained for the attempted solid-state studies 
of the Cu-isoniazid, and Cu-, Ni- and Zn-pyrazinecarboxamide complexes.  
The study commenced with the use of co-precipitation, refluxing and mechanochemical 
methods (neat and liquid-assisted co-grinding) in attempts to synthesise Cu, Ni and Zn 
complexes of a series of anti-tubercular drugs, namely isoniazid, ethambutol, p-amino- 
salicylic acid, pyrazinearboxamide and rifampicin. However, despite exhaustive efforts, all 
experiments resulted in the formation of only physical mixtures of the reactants, as revealed by 
chromatographic and X-ray diffraction methods. This prompted the use of an alternative 
procedure, namely solvothermal synthesis, the results of which are summarised below. 
Attempted solvothermal synthesis using the various combinations of metal salts and ligands 
listed above resulted in the formation of unexpected complex products, for which a 
rationalisation was provided in the previous section.   
Experiments using Cu, Ni and Zn salts with isoniazid and pyrazinecarboxamide resulted in the 
formation of the unexpected complexes Cu(ISONIC)2(H2O)4 (ISONIC = isonicotinate ion), 
Cu(PZONIC)2 (PZONIC = 2-pyrazine-carboxylato ion) and M(PZONIC)2(H2O)2 where (M = 
Ni and Zn). These products were fully characterised using elemental analysis, single crystal 
and powder X-ray diffraction studies, and Fourier transform infrared (FTIR) spectroscopy.  
The coordination environment in Cu(ISONIC)2(H2O)4 as revealed from the X-ray structure 
shows that Cu(II) coordinates with two isonicotinate ligands and four water molecules, 
resulting in a distorted octahedral configuration of CuN2O4 type. From the hydrogen bond data 
(primarily O-HO), it was observed that complex molecules are interconnected in the solid 
state by five crystallographically unique intermolecular hydrogen bonds, generating a final 
three-dimensional supramolecular network. The PXRD pattern of the Cu(ISONIC)2(H2O)4 
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crystal from the present study was in good agreement with that generated from a previously 
reported structure determination. The FTIR spectrum reveals the presence of water of 
crystallisation and the involvement of the pyridine nitrogen atom of the isonicotinate ligand in 
complexation. 
For Cu(PZONIC)2 the coordination environment around Cu(II) indicates that the complex 
displays square-planar geometry, with the ligand acting as bidentate.  The FTIR spectrum 
confirms the coordination of a pyrazine N atom and a carboxylate O atom to the metal centre. 
The PXRD pattern of Cu(PZONIC)2 obtained from the experimental sample prepared in the 
present study and the calculated pattern of the complex structure reported in the literature 
displayed a high level of agreement, providing convincing evidence of the identity of the two 
phases.  
For M(PZONIC)2(H2O)2 where M = Ni and Zn, the crystal structures are both monoclinic, 
crystallising in the space group P21/c, with very similar unit cell parameters, and hence they 
are isostructural. The isostructurality is also established by the close matching of their PXRD 
patterns.  
Based on our finding that attempts to synthesise metal complexes using pyrazinecarboxamide 
and isoniazid ligands via the solvothermal method resulted in complexes containing 
respectively 2-pyrazine-carboxylato (pyrazinoate) and 2-pyridine-carboxylato (isonicotinate) 
ligands, it is concluded that such harsh conditions are unfavourable for producing the target 
complexes.    
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Chapter 6 
 
Concluding Remarks 
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6.1 Conclusion 
The significant role of metals and the recognition of their complexes as important bioactive 
compounds in vitro and in vivo has aroused an ever-increasing interest in these agents as 
potential drugs for therapeutic intervention in various diseases.  
This study was undertaken to develop metal complexes of anti-tubercular drugs with improved 
solubility and absorption properties.  A high rate of absorption for improved bioavailability of 
these drugs is necessary for efficacy against resistant TB strains. In the present study, Cu(II), 
Ni(II) and Zn(II) complexes of a series of anti-tubercular drugs, namely isoniazid (ISO), 
ethambutol (EMB), p-aminosalicylic acid (PAS), pyrazinecarboxamide (PZA) and rifampicin 
(RFN) were studied with the aim of increasing their lipophilicity and permeability.   
Bioavailability is an essential measurement tool since it determines the correct dosage for 
administration of a drug. It refers to the degree and rate at which an administered drug is 
absorbed by the body’s circulatory system.  For metal ions, there is the added complication that 
the bioavailability depends on the speciation or distribution of the metal ion amongst all 
possible species in solution.  It is not possible to measure the metal ion speciation in vivo 
because the number of such species is so large and their concentrations are often below the 
detectable limits of modern analytical chemistry. However, knowing the thermodynamics, 
reflected in the equilibrium constants for the metal ion - ligand interactions, it is possible to 
calculate the speciation under steady-state conditions. 
The protonation/deprotonation constants and the equilibrium of the ligand and metal-ligand 
complexes were measured in aqueous solution at 25  0.01C and an ionic strength of 0.15 M 
(NaCl) using glass electrode potentiometry. The measured protonation constants for ISO were 
3.67 and 10.95, and these constants correspond to the protonation of the pyridine nitrogen and 
the hydrazide group.  The equilibrium constant for the deprotonation of CuISOH (log βMLH- 
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log βML = 13.77 - 8.98) was determined as 4.79.  This value is similar to the pKa of pyridine 
(5.21) which suggests that it is the pyridine that is deprotonated to form ML from MLH. Thus, 
CuLH is formed by the coordination of the isoniazid carbonyl oxygen and hydrazide amino 
nitrogen atoms, while the pyridine group is protonated.  
The log β value for CuISO is 8.98, which is much higher than the stability constants of 
[Cu(II)(NH3)]
2+ (4.8), [Cu(II)(pyridine)] 2.49, and [Cu(II)(benzyhydrazide] 1.73, suggesting 
that the ligand is not monodentate. The log β value is quite close to that of [Cu(II)(en)]2+ (10.5) 
suggesting that the ligand has a similar binding mode. The stability constants (log β values) of 
ML species of ISO with Cu(II), Ni(II) and Zn(II) are 8.98, 4.92 and 5.50 respectively. The 
difference in stability of some 3.5-4.0 log units is observed between Cu(II) and the in vivo 
competitors Ni(II) and Zn(II). The explanation for this observation is that the arrangement of 
the ligand donor atom is such that the Cu(II) ion is constrained to adopt a square-planar 
coordination geometry and Zn(II) prefers a tetrahedral coordination geometry, as observed in 
most simple systems and metalloenzymes.  
In the deprotonation of ML to form MLH-1, for Ni(II) and Zn(II), the calculated pKa (log βML - 
log βMLH-1) values were 8.96 and 7.60.  These values are 0.90 and 1.57 log units lower than the 
first hydrolysis constant of Ni(II) (pKa-OH) = 9.86 and Zn(II) (pKa-OH) = 9.17 respectively. 
This suggests that the deprotonation comes from a coordinated water molecule in the complex.     
EMB has been found to take up two protons in the pH range 2-11. The two pKa values of 6.52 
and 9.63 arise from the two amino nitrogen groups. The log β value for ML in Cu(II) EMB 
(10.4) and [Cu(II)(en)]2+ (10.5) are similar, suggesting similar binding modes.  A noticeable 
feature about the complexation of EMB with Cu(II), Ni(II) and Zn(II) is the prevalence of the 
ML species. The difference in the stability observed between the metal ions with EMB was 3-
4 log units, and the trend agrees with the Irving-Williams stability order for transition-metal 
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complexes. The log β value of ML2 (15.42) compares well with that for [Cu(II)(en)2]2+, namely 
15.9, again suggesting a similar coordination mode. The ML2 can coordinate through the two 
amino nitrogen atoms from the two ligands. The calculated Cu(II)-assisted deprotonation 
constants associated with the formation of ML2H-1 and ML2H-2 are 8.77 and 10.01 respectively. 
The deprotonation could be due to loss of protons from coordinated water molecules since the 
pKa is close to the hydrolysis constant of [Cu(OH2)6]
2+.  
P-aminosalicylic acid displays two pKa values of 3.78 and 1.85 arising from the carboxylic 
acid group and the amino group respectively. The value of the equilibrium constant for the 
deprotonation reaction of CuPASH (log βMLH - log βML = (5.59 – 2.21) = 3.38), suggests that 
the amino nitrogen is protonated in the formation of MLH.  The deprotonation of ML leads to 
the formation of MLH-1 with a pKa of 4.96. The deprotonation occurs at a much lower pH than 
the deprotonation of the phenolic OH group of the free ligand, suggesting a metal ion - induced 
proton loss.  
The protonation constants of rifampicin (RFN) and pyrazinecarboxamide (PZA) could not be 
detected under the conditions of our experiment. The metal complex species of ISO, EMB and 
PAS showed significantly different coordination behaviour at physiological pH. 
Since the distribution of the species has been determined from the potentiometric result, it is 
important to ascertain the structure of the complexes using UV-Visible spectroscopy. The 
maximum wavelength (max) and the absorptivity () of different metal-ligand complexes in 
solution were used to predict the structures of complexes of EMB with Cu(II) and Ni(II) and 
those of ISO and PAS with Cu(II).  The visible spectra obtained are typical of Cu(II) in a 
distorted octahedral environment, and the molar extinction coefficients are also typical of 
Cu(II) complexes and reflect the distortion of the metal-ion environment. The Ni(II) EMB 
spectra display a shift of the complex from octahedral to square-planar.  
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The λmax value for CuISOH (746 nm) is similar to that for [Cu(NH3)(OH2)] (745 nm), 
suggesting that the amine nitrogen atom of ISO is coordinated to the copper, which means that 
the pyridine nitrogen atom is protonated. The experimental λmax values and molar extinction 
coefficients for ML and MLH-1 are estimated as 743 nm, 28.33 dm
3 mol-1 cm-1 and 736 nm, 
8.35 dm3 mol-1 cm-1 respectively.  
In the UV-spectrum of CuPAS, there is a decrease in the λmax value of MLH-1 when compared 
to ML, which can be attributed to deprotonation of the phenolic OH group of the coordinated 
ligand.   For this to occur at such a low pH, the metal ion must be involved in a metal ion - 
induced proton loss, resulting in the spectral change. The results of the spectroscopic studies 
are in agreement with the proposed structure from the potentiometric results.   
Knowing that metal complexes of ISO, PZA, PAS and RFN are stable and having some idea 
as to the structures of the complexes, it is important to study their permeability and 
bioavailability. Partition coefficients are often used as an indication of tissue permeability as 
they are easier to measure than membrane permeability using a Franz cell. This method 
measures the ratio of the concentration of metal-ligand complexes in the lipid phase (octanol) 
to their concentration in the aqueous phase (water). The partition coefficients of ISO and PZA, 
as well as those of their metal complexes, have log values below zero, indicating that the 
ligands and their complexes are hydrophilic. The values of log Poct/aq for PAS and RFN and 
their metal complexes are positive, signifying that they are lipophilic.  
One of the objectives of the study was to develop metal complexes that could improve the 
bioavailability of the parent drugs. This was evaluated by measuring the effect of the metals on 
the rate of diffusion of the ligands through Cerasome, an artificial membrane as a model for 
the skin, using a Franz cell. The presence of Cu(II), Zn(II) and Ni(II) metals enhanced the 
permeation of ISO through the artificial membrane, while zinc improved the permeability of 
164 
 
PAS with an enhancement ratio of 2. The presence of Cu(II), Zn(II) and Ni(II) did not affect 
the permeability of PZA. Cu(II) improved the permeability of RFN 20-fold.  
Potts and Guy1 have developed an empirical relationship between log Poct/aq, log Kp and size (MW) 
of a drug.  We tested this relationship with our results and found that the multiple linear regression 
analysis of log Kp upon log Poct/aq and MW gave an R
2 value of 0.77, which means that there is a 
correlation between log Kp and log Poct/aq or MW.   
The average value of the intercept diffusivity log (D0/h), the constant which accounts for the 
difference between the partitioning domain presented by octanol and the membrane lipids (f), and 
conversion factor for the substitution of molecular weight for molecular volume (β) found in the 
present studies were 0.26, 0.76 and 0.00078 respectively. These values were compared to the 
values of Log (D0/h) (-2.72), f (0.71), and β (0.0061) values obtained by Flynn for 90 drugs.2 The 
diffusivity of these charged complexes of the present studies are higher than expected and f is 
similar as the charge of the complex has a similar effect on the octanol and membrane partitioning.  
This further supports the conclusion that for a labile drug and its complexes, factors other than size 
and partition coefficient are significant. 
Since intravenous (IV) administration requires trained personnel, anti-TB drugs are usually 
administered in tablet form. For this reason, efforts were made to synthesize the metal complexes of the 
drugs in solid form. Techniques which included  co-precipitation,  refluxing and 
mechanochemistry  (neat and liquid-assisted co-grinding) were employed in an attempt to 
synthesise Cu(II), Ni(II) and Zn(II) complexes of the chosen series of anti-tubercular drugs. 
However, upon analysing the products of the experiments using chromatographic and X-ray 
diffraction methods, it was observed that the products obtained were all physical mixtures of 
the starting materials. This prompted the use of the solvothermal method as an alternative 
synthetic technique. The syntheses via this method for the targeted metal complexes of 
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isoniazid and pyrazinecarboxamide resulted in the formation of complexes containing 2-
pyrazine-carboxylato (pyrazinoate) and 2-pyridine-carboxylato (isonicotinate) ligands 
respectively. It was therefore inferred, based on the probable mechanism of transformation, 
that the solvothermal method is unfavourable for obtaining the target complexes. 
The overall results of this study are encouraging and merit further evaluation of metal ions to 
improving the lipophilicity and permeability of anti-tubercular drugs. It is hoped that this study 
has contributed to the understanding of some aspects and factors involved in the development 
of metal complexes for improving absorption of anti-tubercular drugs. 
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